

BMJ Open Protocol of the Berlin Long-term Observation of Vascular Events (BeLOVE): a prospective cohort study with deep phenotyping and long-term follow up of cardiovascular high-risk patients

Joachim E Weber ^{1,2,3,4} Michael Ahmadi ^{1,2} Leif-Hendrik Boldt ^{4,5,6}
 Kai-Uwe Eckardt ^{1,7} Frank Edelmann ^{1,4,5} Holger Gerhardt ^{1,4,8}
 Ulrike Grittner ^{1,9} Kathrin Haubold ¹ Norbert Hübner ^{1,4,8,10,11}
 Jil Kollmus-Heege ^{1,9} Ulf Landmesser ^{1,4,12,13} David M Leistner ¹²
 Knut Mai ^{4,14,15,16} Dominik N Müller ^{1,4,8,10,11} Christian H Nolte ^{1,2,3,4}
 Burkert Pieske ^{1,4,5} Sophie K Piper ^{1,9,17} Simrit Rattan ^{1,9}
 Geraldine Rauch ⁹ Sein Schmidt ^{1,2,3} Kai M Schmidt-Ott ^{1,7,10,18}
 Katharina Schönraht ¹ Jeanette Schulz-Menger ^{4,10}
 Oliver Schweizerhof ^{1,9} Bob Siegerink ^{1,19} Joachim Spranger ^{1,4,14,15,16}
 Vasan S Ramachandran ^{1,20,21} Martin Witzernath ^{22,23}
 Matthias Endres ^{2,3,4,24,25} Tobias Pischon ^{1,4,11,26,27}


To cite: Weber JE, Ahmadi M, Boldt L-H, *et al.* Protocol of the Berlin Long-term Observation of Vascular Events (BeLOVE): a prospective cohort study with deep phenotyping and long-term follow up of cardiovascular high-risk patients. *BMJ Open* 2023;**13**:e076415. doi:10.1136/bmjopen-2023-076415

► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2023-076415>).

JEW and MA contributed equally.

Received 06 June 2023

Accepted 22 September 2023



© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to

Dr Joachim E Weber;
joachim.weber@bih-charite.de

ABSTRACT

Introduction The Berlin Long-term Observation of Vascular Events is a prospective cohort study that aims to improve prediction and disease-overarching mechanistic understanding of cardiovascular (CV) disease progression by comprehensively investigating a high-risk patient population with different organ manifestations.

Methods and analysis A total of 8000 adult patients will be recruited who have either suffered an acute CV event (CVE) requiring hospitalisation or who have not experienced a recent acute CVE but are at high CV risk. An initial study examination is performed during the acute treatment phase of the index CVE or after inclusion into the chronic high risk arm. Deep phenotyping is then performed after ~90 days and includes assessments of the patient's medical history, health status and behaviour, cardiovascular, nutritional, metabolic, and anthropometric parameters, and patient-related outcome measures. Biospecimens are collected for analyses including 'OMICs' technologies (e.g., genomics, metabolomics, proteomics). Subcohorts undergo MRI of the brain, heart, lung and kidney, as well as more comprehensive metabolic, neurological and CV examinations. All participants are followed up for up to 10 years to assess clinical outcomes, primarily major adverse CVEs and patient-reported (value-based) outcomes. State-of-the-art clinical research methods, as well as emerging techniques from systems medicine and artificial intelligence, will be used to identify associations between patient characteristics, longitudinal changes and outcomes.

Ethics and dissemination The study was approved by the Charité—Universitätsmedizin Berlin ethics committee (EA1/066/17). The results of the study will be disseminated through international peer-reviewed publications and congress presentations.

STRENGTHS AND LIMITATIONS OF THIS STUDY

- ⇒ The Berlin Long-term Observation of Vascular Events provides a unique opportunity to foster research on mechanisms that drive disease progression in a heterogeneous cardiovascular high-risk patient population with various organ-manifestations to develop disease-overarching personalised secondary prevention strategies.
- ⇒ The comprehensive collection of data and biospecimens at baseline, as well as during the 10 years follow-up programme, can be used as a platform to address multiple research questions.
- ⇒ Cooperation and data integration with other large ongoing cohorts is enabled by using similar phenotyping protocols (German National Cohort, NAKO); German National Pandemic Cohort Net (NAPKON).
- ⇒ A limitation is that due to the time-consuming deep phenotyping procedures (particularly during the day ~90 visit) the study participation might not be feasible for very severely ill patients resulting in a selection bias. Such a bias may additionally result from the necessity for participants to speak and comprehend German fluently which is required for multiple study measures.
- ⇒ Generalisability of the study population may also be limited by the recruitment setting in a major university hospital.

Study registration First study phase: Approved WHO primary register: German Clinical Trials Register: <https://drks.de/search/de/trial/DRKS00016852>; WHO International

Clinical Registry Platform: <http://apps.who.int/trialsearch/Trial2.aspx?TriallD=DRKS00016852>. Recruitment started on July 18, 2017. Second study phase: Approved WHO primary register: German Clinical Trials Register DRKS00023323, date of registration: November 4, 2020, URL: <http://www.drks.de/DRKS00023323>. Recruitment started on January 1, 2021.

INTRODUCTION

Background and rationale

Despite advances in therapy and prevention,¹ cardiovascular disease (CVD) remains the leading cause of death and permanent disability worldwide.^{2–3} Cardiovascular events (CVE), such as acute coronary syndrome (ACS), acute heart failure (AHF) or acute stroke, share multiple established risk factors,⁴ including type 2 diabetes, hypertension, lipid disorders, obesity, smoking. In clinical practice, the individual risk factor profile is used in algorithms for CVE risk prediction and for prevention decisions.^{5–6} Patients with a CVE are at very high risk for recurrent events and cardiovascular death.⁶ However, individual risk varies substantially even when adhering to current standards of care.^{7–9} Interactions between multiple aspects of health and disease are not fully understood. Interacting factors are, for example, cardiovascular and chronic cardiometabolic comorbidities,¹⁰ behavioural and social factors, and the impact of treatment-related advances on long-term prognosis.¹¹ Furthermore, CVDs are systemic diseases that affect multiple organs.¹² Inter-organ crosstalk is crucially involved in individual disease progression and outcome.

For a more personalised risk stratification and more effective personalised interventions in patients with established CVD, a better understanding of the mechanistic involvement of systemic factors such as immunological processes,^{13–15} metabolic parameters^{12–16} or the gut microbiome¹⁷ is needed. Characterisation of the long-term consequences of the interplay between organs^{18–20} will help to understand the interindividual variability in disease progression and improve the development of interventions to reduce adverse CVD outcomes.

Objectives

The primary goal of the Berlin Long-term Observation of Vascular Events (BeLOVE) is to identify and to characterise risk factors for major adverse cardiovascular events (MACE) among patients at high CVD risk. Secondary objectives include the identification of characteristics and markers associated with mortality, and patient-reported outcomes. Also, BeLOVE aims to promote a cross-disease mechanistic understanding of CVD in high-risk patients to provide the basis for improved, individualised risk management. BeLOVE consists of a cohort of cardiovascular patients with different primary disease entities for comprehensive clinical, functional and molecular phenotyping with extensive collection of biospecimens. It will serve as a resource to identify and characterise novel risk factors in secondary prevention settings.

METHODS AND ANALYSIS

Study design

BeLOVE is a prospective cohort study of patients with either one of three recent acute index CVEs: (1) ACS, (2) AHF, (3) acute ischaemic stroke or transient ischaemic attack (TIA) or non-traumatic intracerebral haemorrhage or (4) patients who are at very high CV-risk as proposed by the European Society for Cardiology^{21–22} but without a history of an acute CVE during the prior 12 months. The key study visits consist of initial phenotyping within 7 days after the acute CVE or within 14 days following study inclusion in the "chronic" CVD arm and comprehensive deep phenotyping after 90 (69–153) days. Participation in at least one of the two visits is a minimal requirement for study continuation. To measure longitudinal changes in exposures or phenotypes additional, more limited visits may be offered to a subset of the participants for up to every 2 years thereafter depending on the availability of additional funding.

The follow-up period will be up to 10 years for all participants for the incidence of MACE and secondary clinical outcomes, and is based on telephone interviews with participants and collection of clinical information from multiple sources (see under Collection of clinical data from medical records and additional sources).

BeLOVE is carried out at facilities of the Berlin Institute of Health (BIH), the Charité—Universitätsmedizin Berlin, and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin (MDC). The governance and management of the study and the institutions involved in the conduction of the study are described in online supplemental figure 1.

Recruitment

Patients are recruited at the Charité—Universitätsmedizin Berlin. The recruitment goal is 8000 participants by 2030. All patients who are admitted to the participating clinical departments of cardiology and neurology with an acute CVE are screened for eligibility to participate based on the criteria listed in [table 1](#) (see online supplemental tables 1 and 2 for more details). Informed consent is obtained during the acute in-hospital phase. Patients who cannot or do not wish to participate in the inclusion visit (acute phenotyping) can postpone consent until the deep phenotyping visit at day ~90 (for details of the visit schedule see [figure 1](#)). Inclusion of patients in the chronic high-risk stratum can be initiated at any time. Candidates are approached and contacted (1) in outpatient clinics, (2) during hospitalisation for any reason and (3) by advertisement in Berlin public transport.

Research visits

The phenotyping of patients during the inclusion visit (see [table 2](#)) focuses on biosampling while day ~90 deep phenotyping additionally includes several technical examinations performed in the BeLOVE clinical unit, BCU (see [table 3](#)). Any deep phenotyping visit that is missed by a participant will be compensated for by an according

Table 1 Inclusion and exclusion criteria

Inclusion criteria	Specification
Age ≥18 years and	
Provision of written informed consent and	
Willingness and ability to participate in the study and	
One of the four following conditions	Acute coronary syndrome* Acute cerebrovascular event* Acute heart failure* Very high-risk chronic cardiovascular conditions without an event in the past 12 months†, that are defined by (at least one of the following) <ul style="list-style-type: none"> ▶ A history of an acute cardiovascular or cerebrovascular event ≥12 months ago. ▶ Significant coronary, carotid or peripheral artery atherosclerosis. ▶ Severe kidney injury. ▶ The combination of diabetes mellitus type 2 and arterial hypertension and hypercholesterolemia. ▶ Diabetes mellitus type 2 with chronic kidney injury or/and with diabetic retinopathy or/and with diabetic neuropathy. ▶ Patients with a very high cardiovascular risk according to the European Society of Cardiology (ESC) SCORE2/SCORE2-OD.
Exclusion criteria	Specification
Inability to give informed consent	
Pregnancy or breastfeeding	
Lack of health insurance	
Reduced life expectancy (<6 months) due to a non-cardiovascular cause	
Active cancer	
A history of organ transplantation	
†More details and criteria to define the CVD inclusion criteria can be found in the online supplemental tables 1 and 2†.	
CVD, cardiovascular disease.	




Figure 1 Overview of the study design. Time ranges given for all study procedures are after an acute event (ACS, AHF, stroke) or study inclusion in the chronic CV-risk arm (Chronic), respectively. Inclusion of patients with acute events is carried out during the acute phase of the event (days 0–7). Acute/initial phenotyping is performed within this period in the acute arms and *within 14 days after inclusion in the chronic CV risk arm. Note that phenotyping at day ~90 is much more comprehensive than at days 0–7. Information on new clinical events provides the source for endpoint adjudication and is captured by repeated search through the hospital information system (HIS) and inquiries to other hospitals, doctors and registration offices in all participants and additional interviews of participants joining the day ~90 and the telephone visits. ACS, acute coronary syndrome; AHF, acute heart failure; CV, cardiovascular; HIS, hospital information system.

Table 2 Overview of the initial phenotyping of the inclusion visit performed in participants within 7 days after an acute CVE or within 14 days after inclusion in the chronic CV risk arm respectively.

Method/measure	Description/content
History, sociodemographics and clinical course	
History and demographics	Medical, family and reproductional history; age, gender, ethnicity
Sociodemographics and health-related behaviour	Education, occupation, family status, household members, need for care, smoking, alcohol consumption, drugs, physical activity and sports
Concomitant medication	Prescribed and non-prescribed
Clinical scales and scores	
Gender questionnaire (modified from Gender index) ⁴⁰	Association of gender and cardiovascular disease
modified Rankin Scale ⁴¹	Poststroke disability scale
New York Heart Association classification ⁴²	Heart failure
Rose dyspnea scale ⁴³	Heart failure
Nutrition and metabolic function	
Glucose monitoring	Continuous 14 days glucose monitoring
Weight and height (BMI)	Self-reported by the participant
Patient reported (value-based) outcomes	
PROMIS-29, ⁴⁴ EQ-5D-5L ⁴⁵	Generic health-related quality of life (QoL)
Stroke: SS-QoL ⁴⁶ ; AHF: MLHFQ, ⁴⁷ KCCQ ⁴⁸ ACS: Seattle Angina Questionnaire, ⁴⁹ Diabetes: ADD-QoL ⁵⁰	Disease-specific QoL
Biosampling	
Blood sample (89,5 mL)	Directly analysed routine parameters, samples for biobanking (serum, plasma, EDTA, including aprotinin and FC mix, citrate), buffy coat and peripheral blood mononuclear cells, TempusTM for DNA and RNA extraction)
Urine	Creatinine, albumin

ACS, acute coronary syndrome; ADDQoL, Audit of Diabetes Dependent Quality of Life; AHF, acute heart failure; BeLOVE, Berlin Long-term Observation of Vascular Events; BMI, body mass index; CVE, cardiovascular event; EQ-5D-5L, EuroQol 5-Dimensions-5-Level; KCCQ, Kansas City Cardiomyopathy Questionnaire; MLHFQ, Minnesota Living with Heart Failure Questionnaire; PROMIS, Patient-Reported Outcomes Measurement Information System; SS-QoL, Stroke-Specific QoL.

telephone visit. For more details of the visit schedule, refer to the supplement.

Inclusion visit

The inclusion visit (see [table 2](#)) contains assessment of the medical and family history as well as health-related behaviour, demographic data, socioeconomic status, gender aspects and several self-assessed measures for value-based outcomes, including Patient-Reported Outcomes Measurement Information System-29 (<http://www.healthmeasures.net>),²³ EuroQol 5-Dimensions-5-Level (<http://www.euroqol.org>)²⁴ and a set of disease-specific measures. A total volume of ~90 mL of blood is collected, an aliquot of which is analysed immediately (see online supplemental table 3). Biomaterials used for biobanking include the remaining venous blood and urine. After preanalytical processing and aliquotation these biosamples are stored in the appropriate medium, either at -80°C or in the vapour phase of liquid nitrogen in the central biobank (for details on biosample processing refer to the supplement). Continuous glucose monitoring for 14 days is initiated before discharge.²⁵

Deep phenotyping visit

Deep phenotyping involves comprehensive examinations carried out in the BCU and the completion of

questionnaires at home. All individuals participating in the 4.5 hour standard deep phenotyping are also asked to participate in additional phenotyping modules lasting an extra ~4 hours (see [figure 2](#) and online supplemental table 4 for more information).

However, since a proportion of participants will not be able to join standard deep phenotyping (e.g., due to health-related issues) a reduced (~1 hour) basic deep phenotyping is offered for them (see [figure 2](#) and [table 3](#)).

The collection of biological samples during standard deep phenotyping follows in principle the same protocol as for the inclusion visit, with additional collection of saliva and stool and a larger blood volume of ~190 mL. In addition to the collection of medical history, sociodemographics and clinical course as well as clinical scales and scores, phenotyping includes comprehensive cardiovascular and cardiopulmonary tests, assessment of anthropometry and vital signs, acquisition of nutrition and metabolic function, different tests of physical activity and neuromuscular function, retinal imaging, as well as cognitive function. Further, health-related patient-reported outcomes are measured. For details, refer to online supplemental table 5.

Table 3 Overview of the standard deep phenotyping performed in participants ~90 days after an acute event or after inclusion in the chronic CV risk arm, respectively

Method/measure	Description/content
History,* sociodemographics* and clinical course*	Education, occupation, family status, household members, need for care, smoking, alcohol consumption, drugs, physical activity and sports; medication; newly made diagnosis or vaccination for COVID-19, newly made diagnosis of diabetes, arterial hypertension, hyperlipidaemia or terminal kidney disease, falls, disease specific symptoms or new treatments, etc.
Clinical scales and scores	modified Rankin Scale, ⁴¹ New York Heart Association classification, Rose dypnoea scale ⁴³ National Institutes of Health Stroke Severity Scale, ⁵¹ Barthel-Index, ⁵² Canadian Cardiovascular Society Score, ⁵³ St. Georges Respiratory Questionnaire, ⁵⁴ Survey of Autonomic Symptoms, ⁵⁵ painDETECT, ⁵⁶ Michigan Neuropathy Screening Instrument. ⁵⁷
Athropometry, nutrition and metabolic function	Height, weight, temperature, blood pressure, pulse, heart frequency, hip-waist-ratio, Air displacement plethysmography (BodPod), Indirect Calorimetry, Metabolic challenge (performed in a subpopulation), Glucose monitoring, Nutrition questionnaire Weikert,* Three Factor Eating Questionnaire*, ⁵⁸ Food Frequency Questionnaire*
CV and cardiopulmonary tests	ECG, pulse wave analysis (Sphygmocor), Ankle brachial index, two-dimensional echocardiography, spiroergometry (performed in a subpopulation), Body Plethysmography
Retinal imaging	Ocular fundus photography, ocular coherence tomography
Physical and neuromuscular function	Hand grip strength test (manual force), Five chair rise test (rising from sitting), Balance Test, 4 m gait speed test, 2 min walk test, Mobile accelerometry (ActiGraph), Physical Fatigue Severity Questionnaire, ⁵⁹ Clinical Frailty Scale ⁶⁰
Cognition	MOntreal Cognitive Assessment, ⁶¹ Cambridge Neuropsychological Test Automated Battery, ⁶² Multi-Choice Vocabulary Intelligence Test, Version A (Mehrfachwahl-Wortschatz-Intelligenztest A), ⁶³ Logic Thinking Subtest-3 (Leistungspruefsyste-3) ⁶⁴
Biosampling	Venous Blood sample (~186.5 mL),* urine,* stool,* saliva sample*
Endpoint research	Structured interview concerning any new hospitalisations, any new myocardial infarction, new-onset angina pectoris, newly made diagnosis or of coronary artery disease, interventional treatment of coronary, carotid, or peripheral artery disease, acute heart failure, aortic dissection or aneurysm, new strokes or transient ischaemic attacks (TIAs), diagnosis or treatment for dementia, depression or anxiety, acute kidney injury or terminal kidney disease
Value-based outcomes	Generic QoL: PROMIS-29, ⁴⁴ EQ-5D-5L, ⁴⁵ SF-36 ⁶⁵ ; Domain-specific QoL: PROMIS: physical function, sleep disturbance, pain behaviour, pain scale intensity, anxiety, depression ²⁶ ; PHQ-8 ⁶⁶ ; Stroke-related QoL: SS-QoL ⁴⁶ ; AHF-related QoL: MLHFQ, ⁴⁷ KCCQ ⁴⁸ ; ACS- related QoL: Seattle Angina Questionnaire ⁴⁹ ; Diabetes- related QoL: ADD-QoL ⁵⁰

*Measures that are also performed during ~1 hour of basic deep phenotyping.

†Patient-reported new events are only considered as endpoints if they can be validated by reviewing medical records (see the section Clinical Endpoints).

ACS, acute coronary syndrome; ADDQoL, Audit of Diabetes Dependent Quality of Life; AHF, acute heart failure; CV, cardiovascular; EQ-5D-5L, EuroQoL 5-Dimensions-5-Level; KCCQ, Kansas City Cardiomyopathy Questionnaire; MLHFQ, Minnesota Living with Heart Failure Questionnaire; PHQ8, Patient Health Questionnaire 8; PROMIS, Patient-Reported Outcomes Measurement Information System; SF-36, Short Form 36; SS-QoL, Stroke-Specific QoL .

BeLOVE also assesses the response to physiological challenges, including a meal challenge and an exercise challenge, to examine the individual metabolism in the postprandial and the exertional state. The nutritional challenge includes a standardised mixed meal (15% protein/45% fat/40% carbohydrates; 500 kcal) after 12 hours of fasting. The physical challenge includes a cardiopulmonary exercise test using a spiroergometry cycle device according to standard operating procedures (SOP) of the German Center for Cardiovascular Research

(DZHK).²⁶ Venous blood samples are taken before and after both challenges.

Optional additional phenotyping ('standard plus') is offered to all participants of the standard deep phenotyping (see figure 2). These additional measures are (refer to online supplemental table 4 for more details): (1) a 1-hour disease-specific set of exams that allow for more sophisticated testing for disease-specific aspects; (2) a 1-hour disease-overarching set of exams with additional specific tests of interest for all disease entities that cannot be implemented within the 4-hour deep phenotyping module due to high expenditure of time and/or financial limitations and (3) MRI, including cardiac, cerebral, pulmonary, kidney and 'metabolic' imaging.




Figure 2 Options for participation in the deep phenotyping (DP) visit ~90 days after the index event. Basic DP is usually reserved for participants with health-related disabilities to join standard DP. The measures of standard and basic DP are enlisted in table 3. Standard plus phenotyping (see supp. table 4) can be joined by all participants of standard deep phenotyping and is performed on a second day.

Telephone visits

Follow-up is carried out by telephone calls at ~day 30, ~day 60 and then biannually for all participants, and includes assessment of clinical endpoints as well as patient-reported outcomes (table 4).

Collection of clinical data from medical records and additional sources

In addition to visit-related data, BeLOVE is integrating health-related information from the clinical context of the acute phase that is available in the Charité hospital information system. Data from medical records are also

**Table 4** Interviews and questionnaires evaluated by annual telephone interviews

Method/measure	Description/content
History, sociodemographics and clinical course	
Sociodemographics and behaviour	See table 2
Concomitant medication	See table 2
Clinical course	See table 3
Clinical scales and scores	
Gender questionnaire (modified from Gender index) ⁴⁰	See table 2
Modified Rankin Scale ⁴¹	See table 2
Barthel Index ⁵²	See table 3
Canadian Cardiovascular Society Score (CCS) ⁵³	See table 3
New York Heart Association classification (NYHA)	See table 2
Rose Dyspnoea Scale ⁴³	See table 2
Cognition	
MOntreal Cognitive Assessment (MoCA) ⁶¹	See table 2
Endpoint interview	
Clinical events interview*	See table 3
Value-based (patient-reported) outcomes	
PROMIS-29, ⁴⁴ EQ-5D-5L ⁴⁵	See table 2
Stroke: SS-QoL ⁴⁶ ; AHF: MLHFQ, ⁴⁷ KCCQ ⁴⁸ ; ACS: Seattle Angina Questionnaire ⁴⁹ ; Diabetes: ADD-QoL ⁵⁰	See table 2
*Interviews for new clinical events (endpoints) are additionally carried out at additional telephone calls every 6 months. Patient-reported events are only considered as endpoints if they can be validated by reviewing medical records (see section on Clinical endpoints adjudication). ACS, acute coronary syndrome; ADD-QoL, Audit of Diabetes Dependent QoL; AHF, acute heart failure; KCCQ, Kansas City Cardiomyopathy Questionnaire; MLHFQ, Minnesota Living with Heart Failure Questionnaire; PROMIS, Patient-Reported Outcomes Measurement Information System; SS-QoL, Stroke-Specific QoL.	

used to validate self-reported history as far as possible (see online supplemental table 5 for more details).

Further, repeated collection of information on new clinical events every 6 months is the basis for endpoint adjudication and uses several sources as described in the supplement (see also online supplemental figure 2).

Clinical endpoints adjudication

Clinical outcomes (endpoints) are assigned by a clearly defined procedure. A specialised team and endpoint committee adjudicates endpoints based on the clinical information gathered as described above. The primary clinical outcome is a composite of MACE defined as non-fatal acute myocardial infarction, non-fatal acute ischaemic or haemorrhagic stroke, hospitalisation for non-fatal AHF, or vascular death (see online supplemental table 6 for more details).

Secondary endpoints include, for example, recurrent myocardial infarction, stroke or heart failure, TIA, any hospitalisation for any reason and all-cause mortality. Definitions and the adjudication process of endpoints are described in more detail in online supplemental figures 3,4 and table 6.

Patient-reported outcomes

Value-based outcomes are patient-reported outcomes measured during study inclusion and ~day 90 deep phenotyping visits as well as telephone visits once a year.

Generic health-related, as well as domain-specific and disease-specific quality of life, is measured by multiple established questionnaires (see online supplemental table 6 for more details).

Incidental findings management

Since the deep phenotyping protocol is expected to produce incidental findings with clinical relevance to the participants BeLOVE has established a standardised findings management. Based on ethical guidelines,^{27–29} evidence-based recommendations from specific medical guidelines, procedures of other studies^{30 31} and our own experience from the first study phase, a standardised operating procedure was developed that defines specific results and their urgency to be communicated and acted on. The concept and first data of incidental findings management will be published separately.

Retention strategy

BeLOVE employs several strategies to improve study adherence and retention, which have been proven to be effective in combination³² (see online supplemental file for more details).

Data management, quality assurance and quality control

Data management and quality assurance/quality control are conducted by a professional data management team and in cooperation with the Clinical Study Center of the

Charité. These fully established structures and processes are described in detail in the supplement.

Statistical methods

Sample size and effect size estimation

BeLOVE is an observational study that aims to address different research questions (see online supplemental table 7). The primary research aim is to identify risk factors for MACE using a comprehensive set of biomarkers and variables from various time points and to develop a prediction model for MACE.

It is assumed that within the 1-year follow-up 8%–12% of the patients experience a new CVE of any type.^{33–35} For a two-sided significance level of 5%, a power of 80%, and no correlation between the predictors and an annual event proportion of 8%, the minimal detectable effect in 7000 participants is HR 1.13, which is lowered to HR 1.10 when a 12% annual incidence of outcome is assumed. A more detailed sample size justification is depicted in the supplement. Since we assume a drop-out rate of around 12%, 8000 patients should be included (see online supplemental figures 5 and 6) for more details).

Statistical analyses

Before analysing the primary and secondary outcomes, detailed statistical analyses plans will be provided. In general, for independent and for outcome variables, depending on their scaling, descriptive measures, such as means, SD, medians, IQRs or absolute and relative frequencies will be reported. Kaplan-Meier survival curves and estimates will be used as descriptive measures for time-to-event data. Analyses will be stratified by index disease entity.

Cox proportional hazards regression,³⁶ adjusted for potential confounders, will be used for the primary analysis to model the association between the exposure variables of interest and the major endpoint (MACE). Time from inclusion into the study (acute event) will be used to calculate person-time at risk until the occurrence of MACE or censoring. Among others, we will use directed acyclic graphs to model the path from exposure to event, and to identify potential confounding or intermediary variables.

Additionally, statistical regression models for recurrent or competing events and structural equation models for time-to-event data will be used to analyse more thoroughly the relations of different markers and characteristics to the outcomes. Continuous outcomes (eg, plasma levels of biomarkers), binary endpoints or ordinal endpoints will be analysed using linear, generalised linear, binary logistic or ordinal regression models. Analyses will be stratified by disease entity of the index event/disease.

Effect estimates and corresponding CIs will be reported where possible and appropriate, instead of reporting ‘statistical significance’, as is recommended by the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline for the reporting of observational studies.³⁷ More details on the planned

statistical analyses methods can be found in online supplemental file 1.

Patient and public involvement

The general concepts, overall research question and the study design were developed without patient involvement. However, all patients will be interviewed about their motivation to participate in the study during the inclusion visit; reasons for study participation and patient’s motivation will be used to improve processes serving to inform and retain patient’s participation. Patients are also informed about clinically relevant findings within the framework of incidental findings management. Furthermore, patients’ representative involvement is planned as part of the data and sample use process. We will develop further patient participation strategies in close cooperation with BIH-QUEST (BIH Center for Transforming Biomedical Research).

Study implementation, results and modifications to the protocol

Recruitment into the BeLOVE study started on 18 July 2017, with an implementation phase, which lasted until 31 December 2020. In this phase, 1939 patients were included (see recruitment, retention and baseline characteristic in online supplemental figure 7 and table 8). During recruitment, it became evident that the study protocol needed to be adapted for logistic and budgetary reasons and the adjustments made are described in detail in online supplemental table 8 and figures 8,9.

The main study phase started on 1 January 2021. By 1 March 2023, 3465 patients have been recruited into the study during all phases combined.

DISCUSSION

BeLOVE is characterised by the following features: (1) inclusion of patients in the acute phase after CVE, (2) long-term follow-up, (3) harmonised application of comprehensive deep phenotyping and (4) acquisition of clinically collected data in a study population that includes both patients after a CVE as well as patients at chronic high risk for a CVE. This approach will enable the identification of risk predictors and pathomechanisms, providing the basis for further investigation and development of personalised strategies for secondary prevention using systemic medicine approaches.

Data collection is largely standardised by using common data elements (CDEs) to allow comparison and combination of BeLOVE with other cohorts (www.nlm.nih.gov/cde). The selection of phenotyping methods not mapped by CDE is the result of scientific exchange and personnel communication with several cardiovascular and population-based studies, such as the population-based Framingham Heart Study³⁸ and the German National Cohort (GNC) study.³⁹ A subset of ‘CVD-free’ participants of the GNC, with no or very few cardiovascular risk factors may serve as a control group for comparison with

the BeLOVE cohort. In addition, standardised processes used for cardiovascular phenotyping were adapted to the SOPs used in clinical studies of the DZHK.²⁶

BeLOVE provides the opportunity to study the short-term and long-term outcomes of patients with high cardiovascular risk. The standardised phenotyping protocol allows to study disease-overarching research questions and thus better understand ‘crossover risk’, as well as the similarities and differences between the different clinical phenotypes. The unique design to follow patients without prior CVE as well as patients in the acute and chronic phase after a CVE allows us to understand and ameliorate potential biases.

ETHICS AND DISSEMINATION

Ethics approval

The BeLOVE study has been approved by the responsible local Ethics Committee of the Charité University Medicine (Charité Campus Mitte; Berlin/Germany; no.EA1/066/17, decision of October 22, 2020). For any changes to the study protocol, we will seek approval by the ethics committee before implementation. The study is conducted in accordance with the Declaration of Helsinki in its current version, Good Epidemiological Practice (GEP) and the applicable German laws. Where applicable, guidelines of the International Conference on Harmonisation of Good Clinical Practice are adhered to.

Informed consent

All study participants are informed comprehensively and with sufficient time for them to reflect on the nature and scope of the study. Written informed consent is obtained from all participants prior to all study-related procedures. Informed consent to participate includes permission to analyse data and samples and to publish all results, at least by the BeLOVE Group.

Data statement

The BeLOVE consortium aims to ensure that the collected data and sample material will be used for the greatest possible benefit to health-related research, in particular cardiovascular research. Researchers interested in the data of BeLOVE may apply for data access through our use and access committee, as long as one member of the project team is part of the BIH research community to support the research process. The use and access committee evaluates the merits and technical feasibility of the project proposal and assesses potential overlap with ongoing projects and analyses. Data transfer will be performed according to established General Data Protection Regulation (GDPR) data sharing guidelines.

Dissemination

We aim to make BeLOVE publications open access to the scientific community, preferably through publication in peer-reviewed open access journals (or the open

access option within subscription journals, golden route to open access), or alternatively by depositing the final accepted version (postprint, maximal 3 months after publication) in the institutional repository of the Freie Universität Berlin (<https://refubium.fu-berlin.de/>) or the Max Delbrück Center (<https://edoc.mdc-berlin.de/>) if possible, as well a conference presentations.

Code availability

Not applicable.

Author affiliations

- ¹Berlin Institute of Health (BIH) at Charité- Universitätsmedizin Berlin, Berlin, Germany
- ²Department of Neurology, Charité- Universitätsmedizin Berlin, corporate member of the Freie Universität Berlin and Humboldt-Universität Berlin, Berlin, Germany
- ³Center for Stroke Research (CSB), Charité- Universitätsmedizin Berlin, corporate member of the Freie Universität Berlin and Humboldt-Universität Berlin, Berlin, Germany
- ⁴German Center for Cardiovascular Research (DZHK), partner site Berlin, Berlin, Germany
- ⁵Department of Internal Medicine and Cardiology, Charité- Universitätsmedizin Berlin, corporate member of the Freie Universität Berlin and Humboldt-Universität Berlin, Berlin, Germany
- ⁶Department of Cardiology, Angiology and Intensive Care Medicine, Deutsches Herzzentrum der Charité (DHZC), Berlin, Germany
- ⁷Department of Nephrology and Medical Intensive Care, Charité- Universitätsmedizin Berlin, corporate member of the Freie Universität Berlin and Humboldt-Universität Berlin, Berlin, Germany
- ⁸Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
- ⁹Institute of Biometry and Clinical Epidemiology, Charité- Universitätsmedizin Berlin, corporate member of the Freie Universität Berlin and Humboldt-Universität Berlin, Berlin, Germany
- ¹⁰Experimental and Clinical Research Center (ECRC), a cooperation of Charité - Universitätsmedizin Berlin and Max Delbrück Center for Molecular Medicine (MDC), Berlin, Germany
- ¹¹Charité- Universitätsmedizin Berlin, corporate member of the Freie Universität Berlin and Humboldt-Universität Berlin, Berlin, Germany
- ¹²Department of Cardiology, Charité- Universitätsmedizin Berlin, corporate member of the Freie Universität Berlin and Humboldt-Universität Berlin, Berlin, Germany
- ¹³Department for Cardiology, Deutsches Herzzentrum der Charité (DHZC), Berlin, Germany
- ¹⁴Department of Endocrinology and Metabolism, Charité- Universitätsmedizin Berlin, corporate member of the Freie Universität Berlin and Humboldt-Universität Berlin, Berlin, Germany
- ¹⁵Center for Cardiovascular Research (CCR), Charité- Universitätsmedizin Berlin, corporate member of the Freie Universität Berlin and Humboldt-Universität Berlin, Berlin, Germany
- ¹⁶German Center for Diabetes Research, München-Neuherberg, Germany
- ¹⁷Institute of Medical Informatics, Charité- Universitätsmedizin Berlin, corporate member of the Freie Universität Berlin and Humboldt-Universität Berlin, Berlin, Germany
- ¹⁸Department of Nephrology and Hypertension, Hannover Medical School, Hannover, Germany
- ¹⁹Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands
- ²⁰Sections of Preventive Medicine and Epidemiology, and Cardiovascular Medicine, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA
- ²¹Department of Epidemiology, Boston University School of Public Health, Boston, Massachusetts, USA
- ²²Division of Pulmonary Inflammation, and Department of Infectious Diseases and Respiratory Medicine, Charité- Universitätsmedizin Berlin, corporate member of the Freie Universität Berlin and Humboldt-Universität Berlin, Berlin, Germany
- ²³German Center for Lung Research (DZL), Germany

²⁴German Center for Neurodegenerative Diseases (DZNE), partner site Berlin, Berlin, Germany

²⁵ExcellenceCluster NeuroCure, Berlin, Germany

²⁶Molecular Epidemiology Research Group, Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany

²⁷Biobank Technology Platform, Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany

Twitter Holger Gerhardt @holger_gerhardt

Acknowledgements We would like to thank the BIH for financial, operational and infrastructural support of this interdisciplinary cohort. Additionally, the authors wish to thank all participants in the BeLOVE pilot and main phase.

Contributors K-UE, FE, ME, HG, NH, UL, DML, KM, DNM, GR, SS, KMS-O, JS-M, BS, JS, BP, TP and JEW developed the idea, the fundamental study design and secured the funding. VSR provided relevant input for the optimisation of the design and the implementation of the study and revised the manuscript critically for important intellectual content. K-UE, ME, UL, BP and JS are the principal investigators for the disease entities included in the study. K-UE, ME, HG, UL, DNM, TP, BP and JS are responsible for the strategic focus of the study and discussed each aspect of student design comprehensively. MA, FE, DML, KM, DNM, SS, KMS-O, JS-M and MW are responsible for the development and implementation of specific modules or aspects of the study. BP, JEW, BS and MA drafted the Manuscript. GR, TP, SKP, UG and BS are responsible for the epidemiological concept and statistical methods. KH, JK-H, SR, KS and OS contributed relevantly to the preparation of the manuscript as well as to the implementation of the BeLOVE study. All authors reviewed the draft and provided feedback and approved the final manuscript to be published. All authors agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Funding The Berlin Institute of Health (BIH) funds the basic infrastructure, recruitment as well as deep phenotyping after 90 days, until December 2024 and long-term telephone follow-up for up to 10 years for all participants (Award/grant number: N/A). The BeLOVE group will apply for further funding from public funding institutions, within the framework of cooperations as well as from companies to assure recruitment and phenotyping beyond 2024. There is no financial remuneration for study participation, except for reimbursement of the transportation cost that patients related to the BTU visits.

Competing interests FE reports grants from German Research Foundation (DFG), grants from German Ministry of Education and Research, grants from the German Herta Foundation; during the conduct of the study; personal fees and non-financial support from Novartis, grants and personal fees from Boehringer Ingelheim, personal fees from CVRx, Pfizer, Medtronic, grants and personal fees from Servier, personal fees from MSD, personal fees from Merck & Co., grants from AstraZeneca, personal fees from Bayer, personal fees from Resmed, personal fees from Berlin Chemie, grants from Thermo Fischer, personal fees from Vifor Pharma, personal fees from PharmaCosmos outside the submitted work; ME reports grants from Bayer and fees paid to the Charité from Abbot, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Daiichi Sankyo, Amgen, Sanofi, Novartis, Pfizer, all outside the submitted work. ME received funding from DFG under Germany's Excellence Strategy – EXC-2049 – 390688087, Collaborative Research Center ReTune TRR 295- 424778381, BMBF, DZNE, DZHK, EU, Corona Foundation, and Fondation Leducq. HG reports grants from the DFG, the Leducq Foundation, the Federal Ministry of Education and Research (BMBF) and the DZHK during the conduct of the study, outside of the submitted work. UL reports research funding from DZHK; Fondation Leducq; research grants from Novartis, Bayer and Amgen. KM declares that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported. DNM received funding for research from Bayer Healthcare, Deutsche Forschungsgemeinschaft and from BMBF. CHN received research grants from German Ministry of Research and Education, German Center for neurodegenerative Diseases (DZNE), DZHK, and speaker and/or consultation fees from Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer Pharma, Abbott, Novartis, Daichii-Sankyo and Alexion all outside the submitted work. BP reports personal fees and other from Bayer Healthcare, personal fees and other from MSD, personal fees and other from Novartis, personal fees from Astrazeneca, grants and personal fees from Servier, personal fees from Medscape, outside the submitted work. No other relationships or activities that could appear to have influenced the submitted work have exist beyond those listed. TP received grants from the BMBF, the Federal Ministry of Food and Agriculture (BMEL), the Federal Ministry for Economic Affairs and Energy (BMWi), the DFG, Deutsche Herzstiftung, German Academic Exchange Service (DAAD). KMSO reports

having consultancy fees with BioPorto Diagnostics; having received license revenue related to the use of a neutrophil gelatinase-associated lipocalin assay via Columbia University; receiving research funding from FAST BioMedical, for being a principal investigator of the EMPAKT-CHF trial, and Quark Pharmaceuticals, for being the site principal investigator for QRK309 trial; and being an editorial board member for *Kidney International* and *Kidney International Reports*; each outside the submitted work. JSM reports grants from Bayer Healthcare, non-financial support from Siemens healthineers, non-financial support from Circle cardiovascular, non-financial support from Medis, outside the submitted work, and Bayer Healthcare, Advisor. Furthermore, funding for research from the EU, DZHK, Deutsche Herzstiftung. JS received funding for research from DFG and from BMBF. MW received funding for research from DFG, BMBF, Deutsche Gesellschaft für Pneumologie, European Respiratory Society, Marie Curie Foundation, Else Kröner Fresenius Foundation, Capnetz Foundation, International Max Planck Research School, Actelion, Bayer Health Care, Biotest, Boehringer Ingelheim, Noxon, Pantherna, Quark Pharma, Vaxxilon, and for lectures and advisory from Actelion, Aptarion, Astra Zeneca, Bayer Health Care, Berlin Chemie, Biotest, Boehringer Ingelheim, Chiesi, Glaxo Smith Kline, Novartis, Noxon, Pantherna, Teva und Vaxxilon. All remaining authors MA, L-HB, K-UE, UG, NH, JK-H, DL, DNM, SKP, SR, GR, KS, OS, BS, SS, RV, JEW do not report potential conflicts of interest.

Patient and public involvement Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.

Patient consent for publication Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iDs

Joachim E Weber <http://orcid.org/0000-0002-1666-6021>
 Michael Ahmadi <http://orcid.org/0000-0001-5792-4704>
 Leif-Hendrik Boldt <http://orcid.org/0000-0002-3320-0880>
 Kai-Uwe Eckardt <http://orcid.org/0000-0003-3823-0920>
 Frank Edelmann <http://orcid.org/0000-0003-4401-5936>
 Holger Gerhardt <http://orcid.org/0000-0002-3030-0384>
 Ulrike Grittner <http://orcid.org/0000-0003-2595-0224>
 Kathrin Haubold <http://orcid.org/0000-0001-5108-5356>
 Norbert Hübner <http://orcid.org/0000-0002-1218-6223>
 Jil Kollmus-Heege <http://orcid.org/0000-0001-5108-5356>
 Ulf Landmesser <http://orcid.org/0000-0002-0214-3203>
 David M Leistner <http://orcid.org/0000-0002-4351-420X>
 Knut Mai <http://orcid.org/0000-0003-0126-3155>
 Dominik N Müller <http://orcid.org/0000-0003-3650-5644>
 Christian H Nolte <http://orcid.org/0000-0001-5577-1775>
 Burkert Pieske <http://orcid.org/0000-0002-6466-5306>
 Sophie K Piper <http://orcid.org/0000-0002-0147-8992>
 Simrit Rattan <http://orcid.org/0009-0006-3684-0660>
 Geraldine Rauch <http://orcid.org/0000-0002-2451-1660>
 Sein Schmidt <http://orcid.org/0000-0002-6698-5717>
 Kai M Schmidt-Ott <http://orcid.org/0000-0002-7700-7142>
 Katharina Schönraht <http://orcid.org/0000-0002-7973-7536>
 Jeanette Schulz-Menger <http://orcid.org/0000-0003-3100-1092>
 Oliver Schweizerhof <http://orcid.org/0000-0002-8954-4818>
 Bob Siegerink <http://orcid.org/0000-0002-8454-9142>
 Joachim Spranger <http://orcid.org/0000-0002-8900-4467>
 Vasan S Ramachandran <http://orcid.org/0000-0001-7357-5970>
 Martin Witzernath <http://orcid.org/0000-0002-9787-5633>

Matthias Endres <http://orcid.org/0000-0001-6520-3720>
Tobias Pischon <http://orcid.org/0000-0003-1568-767X>

REFERENCES

- Virani SS, Alonso A, Aparicio HJ, et al. Heart disease and stroke Statistics-2021 update: A report from the American heart Association. *Circulation* 2021;143:e254–743.
- Joseph P, Leong D, McKee M, et al. Reducing the global burden of cardiovascular disease, part 1: the epidemiology and risk factors. *Circ Res* 2017;121:677–94.
- Leong DP, Joseph PG, McKee M, et al. Reducing the global burden of cardiovascular disease, part 2: prevention and treatment of cardiovascular disease. *Circ Res* 2017;121:695–710.
- Fisher M, Folland E. Acute ischemic coronary artery disease and ischemic stroke: similarities and differences. *Am J Ther* 2008;15:137–49.
- Jaspers NEM, Blaha MJ, Matsushita K, et al. Prediction of individualized lifetime benefit from cholesterol lowering, blood pressure lowering, Antithrombotic therapy, and smoking cessation in apparently healthy people. *Eur Heart J* 2020;41:1190–9.
- Visseren FLJ, Mach F, Smulders YM, et al. ESC guidelines on cardiovascular disease prevention in clinical practice. *Eur Heart J* 2021;42:3227–337.
- Kaasenbrood L, Boekholdt SM, van der Graaf Y, et al. Distribution of estimated 10-year risk of recurrent vascular events and residual risk in a secondary prevention population. *Circulation* 2016;134:1419–29.
- De Bacquer D, Ueda P, Reiner Z, et al. Prediction of recurrent event in patients with coronary heart disease: the EUROASPIRE risk model. *Eur J Prev Cardiol* 2022;29:328–39.
- Gynnild MN, Hageman SHJ, Dorresteijn JAN, et al. Risk stratification in patients with ischemic stroke and residual cardiovascular risk with current secondary prevention. *Clin Epidemiol* 2021;13:813–23.
- Emerging Risk Factors. Association of Cardiometabolic Multimorbidity with mortality. *JAMA* 2015;314:52–60.
- Singh R-J, Chen S, Ganesh A, et al. Long-term neurological, vascular, and mortality outcomes after stroke. *Int J Stroke* 2018;13:787–96.
- Oishi Y, Manabe I. Organ system Crosstalk in Cardiometabolic disease in the age of Multimorbidity. *Front Cardiovasc Med* 2020;7:64.
- Gisterå A, Hansson GK. The Immunology of Atherosclerosis. *Nat Rev Nephrol* 2017;13:368–80.
- Wolf D, Ley K. Immunity and inflammation in Atherosclerosis. *Circ Res* 2019;124:315–27.
- Lawler PR, Bhatt DL, Godoy LC, et al. Targeting cardiovascular inflammation: next steps in clinical translation. *Eur Heart J* 2021;42:113–31.
- Basak T, Varshney S, Hamid Z, et al. Identification of metabolic markers in coronary artery disease using an untargeted LC-MS based Metabolomic approach. *J Proteomics* 2015;127:169–77.
- Witkowski M, Weeks TL, Hazen SL. Gut Microbiota and cardiovascular disease. *Circ Res* 2020;127:553–70.
- Di Lullo L, Reeves PB, Bellasi A, et al. Cardiorenal syndrome in acute kidney injury. *Sem Nephrol* 2019;39:31–40.
- Scheitz JF, Nolte CH, Doehner W, et al. Stroke-heart syndrome: clinical presentation and underlying mechanisms. *Lancet Neurol* 2018;17:1109–20.
- Jensen JK. Risk prediction: are we there yet? *Circulation* 2016;134:1441–3.
- Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of Dyslipidaemias: lipid modification to reduce cardiovascular risk. *Eur Heart J* 2020;41:111–88.
- Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. *Eur J Prev Cardiol* 2022;29:5–115.
- Hinchcliff M, Beaumont JL, Thavarajah K, et al. Validity of two new patient-reported outcome measures in systemic sclerosis: patient-reported outcomes measurement information system 29-item health profile and functional assessment of chronic illness therapy-Dyspnea short form. *Arthritis Care Res* 2011;63:1620–8. 10.1002/acr.20591 Available: <http://doi.wiley.com/10.1002/acr.v63.11>
- EuroQol G. Euroqol—a new facility for the measurement of health-related quality of life. *Health Policy* 1990;16:199–208.
- Alfieri V, Myasoedova VA, Vinci MC, et al. The role of Glycemic variability in cardiovascular disorders. *Int J Mol Sci* 2021;22:8393.
- Deutsches Zentrum Für HERZ-Kreislauf-Forschung E.V. n.d. Available: <https://dzhk.de/forschung/klinische-forschung/sops>
- Heinemann T. Zufallsbefunde bei Bildgebenden Verfahren in der Hirnforschung. *Dtsch Arztebl International* 2007;104:1982.
- Shoemaker JM, Holdsworth MT, Aine C, et al. A practical approach to incidental findings in neuroimaging research. *Neurology* 2011;77:2123–7.
- Wolf SM, Lawrenz FP, Nelson CA, et al. Managing incidental findings in human subjects research: analysis and recommendations. *J Law Med Ethics* 2008;36:219–48.
- Bertheau RC et al. Management of incidental findings in the German national cohort. In: Weckbach S, ed. *Incidental Radiological Findings*. Cham: Springer International Publishing, 2017: 57–70.
- Schlett CL, Hendl T, Weckbach S, et al. Population-based imaging and Radiomics: rationale and perspective of the German national cohort MRI study. *Rofo* 2016;188:652–61.
- Robinson KA, Dinglas VD, Sukrihan V, et al. Updated systematic review identifies substantial number of retention strategies: using more strategies retains more study participants. *J Clin Epidemiol* 2015;68:1481–7.
- Amarenco P. Steering committee investigators of the, risk of stroke after transient ischemic attack or minor stroke. *N Engl J Med* 2016;375:387.
- Jernberg T, Hasvold P, Henriksson M, et al. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. *Eur Heart J* 2015;36:1163–70.
- Maggioni AP. Epidemiology of heart failure in Europe. *Heart Fail Clin* 2015;11:625–35.
- Cox DR. Regression models and life-tables. *J Royal Stat Soc: Series B (Methodological)* 1972;34:187–202. 10.1111/j.2517-6161.1972.tb00899.x Available: <https://rss.onlinelibrary.wiley.com/toc/25176161/34/2>
- Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. *Epidemiology* 2007;18:805–35.
- DAWBER TR, MEADORS GF, MOORE FE Jr. Epidemiological approaches to heart disease: the Framingham study. *Am J Public Health Nations Health* 1951;41:279–81.
- German National Cohort C. The German national cohort: aims, study design and organization. *Eur J Epidemiol* 2014;29:371–82.
- Pelletier R, Ditto B, Pilote L. A composite measure of gender and its association with risk factors in patients with premature acute coronary syndrome. *Psychosom Med* 2015;77:517–26.
- van Swieten JC, Koudstaal PJ, Visser MC, et al. Interobserver agreement for the assessment of handicap in stroke patients. *Stroke* 1988;19:604–7.
- The classification of cardiac diagnosis. *JAMA* 1921;77:1414.
- Rose GA, Blackburn H. Cardiovascular survey methods. *Monogr Ser World Health Organ* 1968;56:1–188.
- Hays RD, Spritzer KL, Schalet BD, et al. PROMIS((R))-29 V2.0 profile physical and mental health summary scores. *Qual Life Res* 2018;27:1885–91.
- Huber MB, Felix J, Vogelmann M, et al. Health-related quality of life of the general German population in 2015: results from the EQ-5D-5L. *Int J Environ Res Public Health* 2017;14:426.
- Ewert T, Stucki G. Validity of the SS-QOL in Germany and in survivors of hemorrhagic or ischemic stroke. *Neurorehabil Neural Repair* 2007;21:161–8.
- Rector TS, Cohn JN. Assessment of patient outcome with the Minnesota living with heart failure questionnaire: Reliability and validity during a randomized, double-blind, placebo-controlled trial of Pimobendan, Pimobendan multicenter research group. *Am Heart J* 1992;124:1017–25.
- Green CP, Porter CB, Bresnahan DR, et al. Development and evaluation of the Kansas City cardiomyopathy questionnaire: a new health status measure for heart failure. *J Am Coll Cardiol* 2000;35:1245–55.
- Spertus JA, Winder JA, Dewhurst TA, et al. Monitoring the quality of life in patients with coronary artery disease. *Am J Cardiol* 1994;74:1240–4.
- Bradley C, Todd C, Gorton T, et al. The development of an individualized questionnaire measure of perceived impact of diabetes on quality of life: the Addqol. *Qual Life Res* 1999;8:79–91.
- Lyden P, Brott T, Tilley B, et al. Improved reliability of the nih stroke scale using video training. ninds tpa stroke study group. *Stroke* 1994;25:2220–6.
- MAHONEY FI, BARTHEL DW. Functional evaluation: the Barthel index. *Md State Med J* 1965;14:61–5.
- Campeau L. Letter: grading of angina Pectoris. *Circulation* 1976;54:522–3.
- Jones PW, Quirk FH, Baveystock CM. The St George's respiratory questionnaire. *Respir Med* 1991;85 Suppl B:25–31;
- Zilliox L, Peltier AC, Wren PA, et al. Assessing autonomic dysfunction in early diabetic neuropathy: the survey of autonomic symptoms. *Neurology* 2011;76:1099–105.

- 56 Freynhagen R, Baron R, Gockel U, *et al.* painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. *Curr Med Res Opin* 2006;22:1911–20.
- 57 Feldman EL, Stevens MJ, Thomas PK, *et al.* A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. *Diabetes Care* 1994;17:1281–9.
- 58 Cappelleri JC, Bushmakina AG, Gerber RA, *et al.* Psychometric analysis of the three-factor eating questionnaire-R21: results from a large diverse sample of obese and non-obese participants. *Int J Obes (Lond)* 2009;33:611–20.
- 59 Krupp LB, Alvarez LA, LaRocca NG, *et al.* Fatigue in multiple sclerosis. *Arch Neurol* 1988;45:435–7.
- 60 Rockwood K, Song X, MacKnight C, *et al.* A global clinical measure of fitness and frailty in elderly people. *CMAJ* 2005;173:489–95.
- 61 Nasreddine ZS, Phillips NA, Bédirian V, *et al.* The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. *J Am Geriatr Soc* 2005;53:695–9.
- 62 The end-to-end platform for CNS clinical trials. 2022. Available: <https://www.cambridgecognition.com/what-we-do/gold-standard-cognitive-research>
- 63 Lehl S, Triebig G, Fischer B. Multiple choice vocabulary test MWT as a valid and short test to estimate Premorbid intelligence. *Acta Neurol Scand* 1995;91:335–45.
- 64 Neubauer AC, Grabner RH, Freudenthaler HH, *et al.* Intelligence and individual differences in becoming Neurally efficient. *Acta Psychol (Amst)* 2004;116:55–74.
- 65 Tarlov AR, Ware JE Jr, Greenfield S, *et al.* The medical outcomes study. an application of methods for monitoring the results of medical care. *JAMA* 1989;262:925–30.
- 66 Kroenke K, Strine TW, Spitzer RL, *et al.* The PHQ-8 as a measure of current depression in the general population. *J Affect Disord* 2009;114:163–73.

Online supplement

Title:

Protocol of the *Berlin Long-term Observation of Vascular Events (BeLOVE)* - a prospective cohort study with deep phenotyping and long term follow up of cardiovascular high-risk patients

Joachim E. Weber^{1,2,3,6} (ORCID: 0000-0002-1666-6021) *; Michael Ahmadi^{1,2,3}(0000-0001-5792-4704) *; Leif-Hendrik Boldt^{5,6,26} (ORCID: 0000-0002-3320-0880); Kai-Uwe Eckardt^{1,4} (0000-0003-3823-0920); Frank Edelmann^{1,5,6} (0000-0003-4401-5936); Holger Gerhardt^{1,6,9} (0000-0002-3030-0384); Ulrike Grittner^{1,10} (0000-0003-2595-0224); Kathrin Haubold¹(0000-0001-5108-5356); Norbert Hübner^{1,6,11,12} (0000-0002-1218-6223); Jil Kollmus-Heege^{1,10} (0000-0003-3183-4932); Ulf Landmesser^{1,6,13} (0000-0002-0214-3203); David Leistner¹³ (0000-0002-4351-420X); Knut Mai^{6,14,15,24} (0000-0003-0126-3155); Dominik N. Müller^{1,6,9, 12 16} (0000-0003-3650-5644); Christian H Nolte^{1,2,3,6} (0000-0001-5577-1775); Burkert Pieske^{1,5,6} (0000-0002-6466-5306); Sophie K. Piper^{1,10,25} (0000-0002-0147-8992); Simrit Rattan^{1,10} (0009-0006-3684-0660); Geraldine Rauch¹⁰ (0000-0002-2451-1660); Sein Schmidt^{1,2,3} (0000-0002-6698-5717); Kai M. Schmidt-Ott^{1,4,11,27} (0000-0002-7700-7142); Katharina Schönraht¹(0000-0002-7973-7536); Jeanette Schulz-Menger^{6,11} (0000-0003-3100-1092); Oliver Schweizerhof^{1,10}(0000-0002-8954-4818); Bob Siegerink^{1,17}(0000-0002-8454-9142); Joachim Spranger^{1,6,14,15,24} (0000-0002-8900-4467); Ramachandran S. Vasani^{1,19,20} (ORCID: 0000-0001-7357-5970); Martin Witzernath^{18,21} (0000-0002-9787-5633); Matthias Endres^{2,3,6,7,8}(0000-0001-6520-3720); Tobias Pischon^{1,6,12, 22,23} (ORCID: 0000-0003-1568-767X)

1 Berlin Institute of Health at Charité – Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany

2 Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Center for Stroke Research Berlin, Berlin, Germany,

3 Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Neurology, Berlin, Germany,

4 Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Nephrology and Medical Intensive Care, Berlin, Germany

5 Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Internal Medicine and Cardiology, Berlin, Germany,

6 German Centre for Cardiovascular Research (DZHK), partner site Berlin, Berlin, Germany

7 German Center for Neurodegenerative Diseases (DZNE), partner site Berlin, Berlin, Germany

- 8 *ExcellenceCluster NeuroCure, Berlin, Germany*
- 9 *Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany*
- 10 *Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, Institute of Biometry and Clinical Epidemiology*
- 11 *Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, ECRC, Department of Cardiology, Berlin, Germany*
- 12 *Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany*
- 13 *Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Cardiology, Berlin, Germany,*
- 14 *Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Endocrinology & Metabolism, Berlin, Germany,*
- 15 *Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charité-Center for Cardiovascular Research (CCR), Berlin, Germany*
- 16 *Experimental and Clinical Research Center (ECRC), a cooperation of Charité - Universitätsmedizin Berlin and Max Delbrück Center for Molecular Medicine (MDC), Berlin, Germany*
- 17 *Leiden University Medical Center, Department of Clinical Epidemiology, Leiden, Netherlands*
- 18 *Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Division of Pulmonary Inflammation, and Department of Infectious Diseases and Respiratory Medicine, Charitéplatz 1, 10117 Berlin, Germany.*
- 19 *Sections of Preventive Medicine and Epidemiology, and Cardiovascular Medicine, Department of Medicine , Boston University School of Medicine, Boston, Massachusetts, USA;*
- 20 *Department of Epidemiology, Boston University School of Public Health, Boston, Massachusetts, USA, USA*
- 21 *German Center for Lung Research (DZL)*
- 22 *Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Molecular Epidemiology Research Group, Berlin, Germany*
- 23 *Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Biobank Technology Platform, Berlin, Germany*
- 24 *German Center for Diabetes Research, München-Neuherberg, Germany*
- 25 *Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Medical Informatics*
- 26 *Deutsches Herzzentrum der Charité, Department of Cardiology, Angiology and Intensive Care Medicine, Augustenburger Platz 1, 13353 Berlin, Germany*
- 27 *Hannover Medical School, Department of Nephrology and Hypertension, Hannover, Germany*

* equal contributions

Corresponding authors:

Prof. Dr. med. Tobias Pischon, Deputy Spokesperson of the BeLOVE study

Group Leader, Molecular Epidemiology Research group Max-Delbrück-Center for Molecular
Medicine (MDC)

Robert-Rössle-Straße 10

13125 Berlin, Germany

Tel.: +49 30 94064563

tobias.pischon@mdc-berlin.de

Dr. med. Joachim E. Weber, Scientific Officer of the BeLOVE study,

Berlin Institute of Health (BIH)

Anna-Louisa-Karsch-Str. 2, 10178 Berlin,

Tel. +49 30 450543524

Fax +49 30 4505437524


joachim.weber@bih-charite.de

Sponsor:

Charité – Universitätsmedizin Berlin,

Charitéplatz 1, 10117 Berlin, Germany

Structures for study planning and execution



Supp. figure 1: Institutions and structures involved in the execution of BeLOVE: SAB = Scientific Advisory Board; Cardio-CRU = Cardiological Clinical Research Unit; MRI = Magnetic Resonance Imaging; ECRC = Experimental and clinical Research Center; BCAN = Berlin Center for Advanced Neuroimaging (Charité); DHZC = German Heart Center Charité; BCRT = BIH Center for Regenerative Therapies

The study is funded by the *Berlin Institute of Health (BIH)*. The study concept, governance and financial plan was evaluated and approved by the international BeLOVE Scientific Advisory Board (SAB). The operative and scientific strategy is determined by the BeLOVE Executive and Scientific Board which is an assembly of principal investigators of the *Charité – Universitätsmedizin Berlin* from the fields of cardiology, neurology, nephrology, endocrinology, pneumology, infectiology, biostatistics, of the Charité and of the *Max-Delbrück Center for Molecular Medicine Berlin (MDC)* from the fields of epidemiology, basic cardiovascular and metabolism research. The study is open to multiple externally funded subproject initiatives with different partners within the BIH, Charité and MDC as well as from other cohorts (e.g. the German National Cohort, NAKO).

The BeLOVE Office is the central project managing and controlling facility that is coordinating the execution of all strategic decision as well as cooperations, endpoint adjudication and finances/funding.

The study is executed by the following institutions:

- Recruitment is carried out by professional clinical trial teams of the Charité's departments for cardiology, neurology and endocrinology
- Patient visits including all phenotyping is performed by the studys own BeLOVE Trial Unit (BTU) at different Campuses of the Charité in Berlin.
- Specialized personal of the BTU is also performing all telephone visits and research for relevant new clinical events (endpoints)
- Echocardiography is carried out under supervision of the Charité department for cardiology
- MRI is performed and analyzed by the department for neuroradiology of the Center for Stroke Research Berlin (CBS), the Berlin Center for Advanced Neuroimaging (BCAN), the Experimental and Clinical Research Center (ECRC) of the MDC and Charité Berlin and the German Heart Center Charité (DHZC). Further, data from metabolic MRI is analyzed by the department of radiology at Universität Tuebingen and pulmonary and kidney MRI at the department of radiology of the Klinikum Rechts der Isar at the Technische Universität Munich (TUM)
- Biobanking is performed by the BIH Biobank Core Facility.
- Blood samples are analyzed for routine measures by Labor Berlin
- Induced pluripotent stem cells are programmed at the MDC
- Immunophenotyping is performed by the BIH Center for Regenerative Therapies (BCRT)
- Proteomics analyses are performed by the Core Facility Proteomics (BIH)

- Metabolomics analyses are performed by the Core Facility Metabolomics (BIH)
- Microbiome analyses are performed at the MDC.
- Genomics analyses are performed at the MDC
- Integration of OMICs data is performed by the Core Unit Bioinformatics (CUBI) (BIH)

Inclusion criteria

Specific inclusion criteria: acute cardiovascular event (CVE) group

Supp. table 1: Detailed specific inclusion and exclusion criteria for the acute CVE group

Specific inclusion criteria: acute CVE events	
Hospitalization for acute heart failure (AHF)	<ul style="list-style-type: none"> • AHF \geq NYHA II <i>OR</i> clinical deterioration of chronic heart failure* AND • escalation of preexisting loop diuretic therapy <i>OR</i> new prescription of loop diuretic therapy <p><i>*exception: if the main primary diagnosis is not AHF but acute coronary syndrome, acute stroke or acute kidney injury, patients shall not be included in the study</i></p>
Hospitalization for acute coronary syndrome (ACS)	<p>characteristics of cardiac chest pain <i>OR</i> angina equivalents AND</p> <p>electrocardiographic manifestations of STE-ACS (ST-segment elevation in \geq two contiguous leads with the cut-points: \geq 2.5mm in men < 40 years; \geq 2.0 mm in men \geq40 years; \geq 1.5mm in women regardless of age in the leads V2/V3 <i>OR</i> ST-segment elevation \geq 1.0 mm in the other leads <i>OR</i> new-onset of LBBB/RBBB <i>OR</i> ST-segment changes in the presence of a preknown BBB <i>OR</i> ST-segment depression in \geq 8 leads in the presence of ST-segment elevation in aVR/V1 <i>OR</i> the presence of pathological Q-waves) <i>OR</i> electrocardiographic manifestations NSTEMI-ACS (Horizontal ST-segment depression of \geq 0.5mm <i>OR</i> T-wave inversions of \geq 1mm in at least 2 contiguous leads) <i>OR</i></p> <p>laboratory evidence of myocardial necrosis (detection of elevation of hs-TnI or hs-TnT greater than the 99th percentile of UR <i>OR</i> normal hs-Tn baseline values at (hospital) admission with a dynamic change in hs-Tn values within 1 hour, confirmed through a TnI-TnT specific assay)</p>
Hospitalization for acute cerebrovascular disorders	

- a. TIA an acute-onset neurological deficit with clinical restitution within 24 hours without evidence for acute ischemia or hemorrhage on imaging AND initial neurological deficit was verified by a neurologist OR ABCD2-Score ≥ 3 OR main hospital diagnosis is amaurosis fugax
- b. Ischemic stroke
- an acute-onset neurological deficit lasting more or less than 24hrs with a fresh ischemic lesion on neuroimaging (MRI or CT) **OR** for patients that did *not* receive cerebral MR imaging during the acute phase*: acute-onset typical cerebrovascular clinical syndrome without a definite fresh ischemic lesion on CT-imaging but with symptom duration > 24hrs **OR** acute monocular vision impairment and evidence for retinal central artery occlusion
- * pts. with a symptom duration > 24h, who received cerebral MRI-imaging including diffusion- and T2*-weighted sequences during the acute phase that did not show acute diffusion-restriction or fresh intracerebral hemorrhage *cannot* be included
- c. non-traumatic intracerebral hemorrhage
- an acute-onset neurological deficit **AND**
 - evidence for fresh intracerebral hemorrhage on neuroimaging (MRI or CT)

Specific Inclusion and exclusion criteria: chronic very high CV-risk group

The very high risk criteria are in accordance with the recommendations of the ESC/EAS-guidelines for the management of lipid disorders[1] and cardiovascular disease prevention.[2]

Supp. table 2: Detailed specific inclusion and exclusion criteria for the chronic CV-risk group

Specific inclusion criteria: chronic CV-risk group

At least 1 out of the following 8 definitions conditions

- 1.) CV events ≥ 12 months ago**
- non-traumatic hemorrhagic stroke, ischemic stroke (including central retinal artery occlusion) or TIA ≥ 12 months ago OR
 - a history of acute coronary syndrome or myocardial infarction ≥ 12 months ago
- 2.) Atherosclerosis**
- Coronary artery calcium score >100 on coronary CT **OR**
 - Significant atherosclerosis on coronary angiography **OR**
 - Coronary artery revascularization (PCI, stenting, cardiac bypass surgery)
 - OR** Carotid artery stenosis $\geq 50\%$ **OR**
 - History of carotid artery revascularization (TEA or stenting) **OR**

- Significant peripheral artery disease ($\geq 50\%$ stenosis, PCI, stenting, bypass surgery or amputation))
- 3. Severe chronic kidney injury**
- GFR < 30 ml/min per 1,73 m² *OR*
 - GFR 30-44 ml/min pro 1,73 m² AND Albumin Creatinin-Ratio (ACR) > 30 mg/g
- 4. Diabetes mellitus type 2 AND arterial hypertension AND hypercholesterolemia**
- diabetes mellitus type 2: pathological findings in oral glucose tolerance test *OR* documented HbA1c $\geq 6.5\%$ *OR* intake of any antidiabetic medication *OR* fasting blood glucose ≥ 126 mg/dl *AND*
 - arterial hypertension \geq grade 1: blood pressure of $\geq 140/90$ mmHg *OR* intake of anti-hypertensive drugs *AND*
 - hypercholesterinemia: LDL-cholesterol > 130 mg/dl *OR* intake of a lipid-lowering medication that was initiated to treat dyslipoproteinemia
- 5. Diabetes mellitus type 2 AND at least moderate diabetic kidney injury**
- Diabetes mellitus type 2 (see 4.) *AND*
 - estimated glomerular filtration rate (eGFR) < 60 ml per minute per 1.73 m² (according to the creatinine-based Chronic Kidney Disease Epidemiology Collaboration equation) *OR* requirement of renal replacement therapy *OR* urinary albumin concentration > 20 mg/l *OR* 24hour albumin excretion > 30 mg/24hours *OR* urinary albumin to creatinine ratio > 30 mg/g
- 6. Diabetes mellitus type 2 AND diabetic retinopathy**
- Diabetes mellitus type 2 (see 4.) *AND*
 - documented fundoscopic lesions (e.g., microneurysms, intraretinal hemorrhage, diabetic maculopathy), former laser therapy, former injection therapy, former vitrectomia, former intervention because of neovascular glaucoma (Nationale Versorgungsleitlinie diabetische Netzhautkomplikationen, 2015)
- 7. Diabetes mellitus type 2 AND diabetic neuropathy**
- Diabetes mellitus type 2 (see 4.) *AND*
 - neuropathy defined as ≥ 2 of the following: decreased/ absent ankle jerk reflexes and/or decreased distal sensory perception (touch/pressure, vibration (dorsal hallux: < 30 yrs: $< 6/8$; > 30 yrs: $< 5/8$; medial malleolus: < 40 yrs.: $< 6/8$; > 40 yrs: $< 5/8$), pain, temperature) and/or neuropathic symptoms (MNSI, NDS, NSS) *OR* neuropathy as evident by neurophysiological examination (neurography +/- EMG) *OR* small-fiber neuropathy as evident by skin biopsy)
- 8. patients without any history of CVE, atherosclerosis Diabetes or familial hypercholesterinemia but with very high cardiovascular risk**
- < 50 years: CV-risk SCORE2 $\geq 7,5\%$.
 - $50-60$ years: CV-risk SCORE2 $\geq 10\%$
 - ≥ 70 years: CV-riksk SCORE2-OD $\geq 15\%$
- (SCORE2/SCORE2-OD was calculated for a European moderate risk-region using the ESC-CVD-Risk-Calculation-App)

according to SCORE2/ SCORE2-OD (<https://www.escardio.org/Education/ESC-Prevention-of-CVD-Programme/Risk-assessment/esc-cvd-risk-calculation-app>)

Specific exclusion criteria: chronic CV-risk group

a < 12 months history of one of the following acute events (as defined by the inclusion criteria for the acute trigger event group)	acute coronary syndrome or myocardial infarction hospitalization for acute heart failure ischemic or hemorrhagic stroke (including retinal central retinal artery occlusion) hospitalization for transitory ischemic attack (TIA) (including Amaurosis fugax)
-------------------------------------------------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Research visits

Blood and urine samples: parameters analysed immediately during study visits

Supp. table 3: Blood and urine analysis performed immediately at the day of the inclusion visit and the day of deep phenotyping respectively

Blood sample	
Hematology	<ul style="list-style-type: none"> hemoglobin, hematocrit blood cell count and differential white blood cell count fibrinogen
Clinical chemistry/biochemistry	<ul style="list-style-type: none"> electrolytes (sodium, potassium, chloride, calcium, inorganic phosphate, magnesium) creatinine, urea, estimated glomerular filtration rate (eGFR), cystatin c total cholesterol (TCHOL), high density lipoprotein (HDL) cholesterol, non-HDL cholesterol, low density lipoprotein (LDL) cholesterol, lipoprotein a (LP-A), triglycerides lipase uric acid glycated hemoglobin (HbA1c) liver transaminases (ALT, AST, GGT), alkaline phosphatase (aP), total bilirubin, lactate dehydrogenase (LDH) total iron binding capacity (TIBC), transferrin, ferritin total protein, albumin partial thromboplastin time (aPTT), thromboplastin time (TP, quick), international normalized ratio (INR) creatin kinase (CK), CK muscle/brain (CK-MB), high sensitive troponin (hsTroponin) MR pro atrial natriuretic peptide (MR-proANP), NT pro brain natriuretic peptide (NT-proBNP), copeptin glucose, proinsulin, insulin, c-peptide, homeostasis model assessment (HOMA-IR) 25-OH-vitamin D thyroid stimulating hormone (TSH), ft3, ft4
Immunology	<ul style="list-style-type: none"> interleukin 6 (IL-6)

	<ul style="list-style-type: none"> • high sensitive procalcitonin (PCT) • high sensitive c-reactive protein (hsCRP)
Urine	
	<ul style="list-style-type: none"> • albumin, creatinine, albumin/creatinine ratio

Deep phenotyping visits: Standard plus program

Supp. table 4: Overview of the (optional) standard plus deep phenotyping, that may be joined by all participants of standard deep phenotyping

Disease overarching measures	
Cardiovascular function	24h ECG and 24h blood pressure
Glucose metabolism	cutaneous Advanced Glycation End product (AGE) accumulation
Disease specific measures [study arm]	
Carotid ultrasound [ACS, AHF, Reference]	Intima Media Thickness (IMT); Plaque qualitatively
Electroencephalography (EEG) [Stroke]	3 min neuronal resting state EEG
Physical activity extended [Stroke, ACS, AHF]	[Stroke]: 9-Hole-Peg-Test, 2min finger tapping test [ACS, AHF]: 6-minute-walk test
Somatosensory function testing [Stroke, chronic risk]	cold/warmth detection thresholds (QST), vibration threshold, touch perception, achilles tendon reflexes, sural neurography (point of care)
Magnet Resonance Imaging (MRI)	
cranial MRI	neuroimaging
cardial MRI	cardial muscle and valve imaging
pulmonary MRI	
kidney MRI	
metabolic MRI	liver fat, intraabdominal fat, abdominal subcutaneous fat

Biosample processing

One part of the blood- and urine sample that is collected from the patients is send to our local laboratory (Labor Berlin) for immediate analysis of routine clinical parameters, while the other part is prepared at the BeLOVE Trial Unit`s (BTU) own preanalytical lab for biobanking. .The following probes are processed and aliquoted before transfer to the biobank (all tubes are labelled with 2D barcodes):

- Serum: standing for 30-35 min at room temperature (RT), centrifugation at 2500g for 10 min (RT), pooled, aliquoting in 0.5 ml tubes (storage at -80°C) and 0.25 ml tubes (storage in the liquid phase of nitrogen).
- EDTA (whole blood): aliquoting in 0.5 ml tubes (storage at -80°C) and 0.25 ml tubes (storage in the liquid phase of nitrogen)
- EDTA (buffy coat): direct centrifugation at 2500g for 10 min (RT), aliquoting in 0.5 ml tubes (storage at -80°C) and 0.25 ml tubes (storage in the liquid phase of nitrogen)
- EDTA (plasma): direct centrifugation at 2500g for 10 min (RT), aliquoting in 0.5 ml tubes (storage at -80°C) and 0.25 ml tubes (storage in the liquid phase of nitrogen)
- EDTA (aprotinin-plasma): direct centrifugation at 2500g for 10 min (RT), aliquoting in 0.5 ml tubes (storage at -80°C) and 0.25 ml tubes (storage in the liquid phase of nitrogen)
- EDTA (citrate-fluoride-plasma): direct centrifugation at 2500g for 10 min (RT), aliquoting in 0.5 ml tubes (storage at -80°C) and 0.25 ml tubes (storage in the liquid phase of nitrogen)
- Heparine (PBMC): isolation, aliquoting in 1.9 ml tubes (from 20ml starting material), storage in the liquid phase of nitrogen
- Heparine (plasma): direct centrifugation at 2500g for 10 min (RT), aliquoting in 0.5 ml tubes (storage at -80°C) and 0.25 ml tubes (storage in the liquid phase of nitrogen)
- Citrate (plasma): direct centrifugation at 2500g for 15 min (RT), aliquoting in 0.5 ml tubes (storage at -80°C) and 0.25 ml tubes (storage in the liquid phase of nitrogen)
- Cellular Preparation Tubes (PBMC): isolation, aliquoting in 1.9 ml tubes (from 20ml starting material), storage in the liquid phase of nitrogen
- Tempus: upright for 2h (RT), for 24h at -20°C, then storage at -80°C Urine: centrifugation at 2500g for 10 min (RT), pooled, aliquoting in 2.0 ml tubes with a 2D barcode, storage at -20°C/-80°C and in liquid nitrogen.

- Stool/feces: storage in OMNIgeneGut tubes at 0°C
- Peripheral blood mononuclear cells (PBMC): isolated and cryconserved in liquid nitrogen

Collection of clinical data from medical records concerning history and the index event

Supp. table 5 Data concerning medical history and the treatment of the index event collected from medical records from the HIS

Data concerning medical history	
Cardiovascular	<ul style="list-style-type: none"> • Acute/ chronic heart failure; Cardiomyopathies, Cardiac contractility management • Acute myocardial infarction; Coronary artery disease, interventional therapy • Arterial hypertension; Atrial fibrillation; Cardiac pacemaker • Endocarditis; Myocarditis • Aortic aneurysm, interventional therapy, Persistent foramen ovale, interventional closure
Cerebrovascular/ neurological	<ul style="list-style-type: none"> • Acute stroke; TIA; Intracerebral hemorrhage; Carotid artery stenosis, interventional therapy; Cerebral aneurysm, interventional therapy • Epilepsy; Parkinson's disease; Polyneuropathy
Peripheral vascular	<ul style="list-style-type: none"> • Peripheral artery disease, interventional therapy • Pulmonary artery embolism
Metabolic	<ul style="list-style-type: none"> • Diabetes • Hyperlipidemia, Hypercholesterolemia, Hypertriglyceridemia • Hyperuricemia, gout • Thyroid disorders
Psychiatric	<ul style="list-style-type: none"> • Anxiety disorder; Dementia; Depression
Behavioral	<ul style="list-style-type: none"> • Smoking; Alcohol addiction
Other	<ul style="list-style-type: none"> • Acute/ chronic kidney injury • Cancer, type of cancer, active vs. in remission • CIBD • Chronic viral infections, type of infection • Collagenosis, type of collagenosis • MGUS • Nephritis • Polymyalgia rheumatic • Psoriasis • Retinal disease • Sarcoidosis • Thrombophilia, type of thrombophilia • Vasculitis, type of vasculitis
Data concerning the index event	

All arms	<ul style="list-style-type: none"> Acute infection any of the diseases described under medical history, if they were newly diagnosed during the index event treatment Echocardiography (if performed) ECG
AHF arm	<ul style="list-style-type: none"> clinical symptoms; prior therapy; NT-pro-BNP; HFpEF; ECG
ACS arm	<ul style="list-style-type: none"> type of ACS; symptoms; mode of admission; door-to-groin puncture time; coronary interventional therapy; blood pressure, heart rate on admission; non-interventional therapy
Stroke arm	<ul style="list-style-type: none"> type of stroke; symptom duration; type of imaging and result of imaging for TIA and ischemic stroke: ABCD² Score for ischemic stroke: NIHSS and mRS on admission and discharge, clinical symptoms, stroke localization (vascular territory, anatomical), reperfusion therapy (if performed, type), blood pressure and sugar on admission, intervention for carotid artery stenosis, stroke etiology (TOAST)
<p><i>Abbreviations:</i> CIBD, Chronic Inflammatory Bowel Disease; HFpEF, Heart Failure with preserved Ejection Fraction; MGUS, Monoclonal Gammopathy of Unknown Significance; NIHSS, National institute of Health Stroke severity Scale; mRS, modified Rankin Scale; TOAST, Trial of ORG 10172 classification of stroke etiology</p>	

Outcome measures: Definition

Supp. table 6: Main event- and value-based outcome measures of BeLOVE. Event-based outcomes are specific clinical events occurring during observation specified by clear endpoint definitions (for the process of endpoint adjudication, all endpoints are defined in more detail in a comprehensive endpoint repository). Value-based outcomes on the other hand are those that are directly reported by with no direct interpretation processing by the investigations

Event-based outcomes (clinical endpoints)	
Primary endpoint = the first major adverse cardiovascular event (MACE), that is a composite of:	<i>specification</i>
○ non-fatal myocardial infarction (MI) or	acute MI type 1 or MI type 4b or MI type 4a or MI type (each STEMI or NSTEMI) or MI Type 2
○ non-fatal stroke or	ischemic stroke (documented diagnosis of acute ischemic stroke and typical clinical symptoms presenting for ≥ 24 hrs or typical clinical symptoms presenting for < 24 hrs with evidence for acute ischemia on CT- or MR imaging) or non-traumatic intracerebral hemorrhage (acute clinical symptoms and imaging evidence for a brain parenchyma hemorrhage)
○ hospitalization for heart failure or	clinical manifestation heart failure (at least one sign: dyspnea, orthopnea, paroxysmal nocturnal dyspnea, edema, pulmonary basilar crackles, jugular venous distension requiring at least 12 hrs of hospitalization, third heart sound or gallop rhythm, radiological evidence of worsening heart failure) AND heart failure is requiring hospitalization AND additional/increased therapy (at least one: initiation of oral diuretic or IV diuretic or inotrope therapy or vasodilator therapy or uptitration of oral or intravenous therapy if already under therapy or initiation of mechanical or surgical intervention or the use of ultrafiltration, hemofiltration, or dialysis that is specifically directed at the treatment of alteration of biomarkers subsequent to heart failure
○ cardiovascular death	fatal myocardial infarction (death within 14 days after MI without evidence for another cause of death) or sudden cardiac death (witnessed vs. unwitnessed) or fatal new or worsening

	heart failure (including fatal cardiogenic shock) or fatal cerebrovascular disease (death within 30 days following a documented ischemic stroke, non-traumatic intracerebral hemorrhage, non-traumatic SAH cerebral vein thrombosis without evidence for another cause of death) or fatal cardiac arrhythmia or fatal cardiac valve disease or fatal coronary catheterization or fatal coronary or carotid or cerebral artery intervention or fatal aortic aneurysm or fatal mesenteric infarction or fatal ischemia of the extremities or fatal pulmonary artery embolism
Secondary endpoints *	specification
cardiovascular	
<ul style="list-style-type: none"> ▪ recurrent myocardial infarction (MI) ▪ MI following stroke or acute heart failure (AHF) ▪ unstable angina pectoris ▪ coronary artery revascularization ▪ hospitalization for suspected MI ▪ any hospitalization for diagnostic cardiac catheterization ▪ recurrent AHF ▪ AHF following MI or stroke ▪ terminal heart failure therapeutic intervention ▪ severe cardiac arrhythmia ▪ heart valve surgery 	<p>any MI occurring in a participant for whom a prior MI was the composite primary endpoint</p> <p>any MI occurring in a participant for whom a prior stroke or acute heart failure that was the composite primary endpoint hospitalization for unstable angina that does not meet criteria of STEMI or NSTEMI</p> <p>urgent vs. elective endovascular revascularization or bypass surgery</p> <p>any hospitalization that ruled out MI</p> <p>cardiac catheterization without revascularization</p> <p>any AHF occurring in a participant for whom a prior AHF episode was the composite primary endpoint</p> <p>any AHF occurring in a participant for whom a stroke or a MI was the composite primary endpoint</p> <p>ventricular assist device implantation, heart transplantation hospitalization for ventricular tachycardia or bradycardia; cardiac pacemaker implantation; hospitalization for or diagnosis of atrial fibrillation</p> <p>open heart surgery; TAVI</p>
cerebrovascular	
<ul style="list-style-type: none"> ▪ recurrent stroke ▪ stroke following MI or AHF ▪ acute revascularization of acute ischemic stroke ▪ transient ischemic attack (TIA) ▪ carotid artery revascularization ▪ persistent foramen ovale (PFO) intervention ▪ subarachnoid hemorrhage (SAH) ▪ cerebral aneurysm intervention ▪ cerebral vein thrombosis 	<p>any stroke occurring in a participant for whom a prior stroke that was the composite primary endpoint</p> <p>any stroke occurring in a participant for whom a prior AHF episode or MI that was the composite primary endpoint</p> <p>therapeutic thrombolysis; endovascular thrombectomy</p> <p>typical transient acute cerebral symptoms with no correlate in cerebral MRI imaging</p> <p>endarterectomy; stenting, extra-intracranial bypass surgery</p> <p>PFO closure for secondary stroke prevention</p> <p>any non-traumatic SAH</p> <p>surgical or endovascular treatment of a cerebral aneurysm</p> <p>cortical, cerebral sinus or internal cerebral vein thrombosis</p>
peripheral vascular	
<ul style="list-style-type: none"> ▪ amputation for peripheral artery disease (PAD) ▪ PAD revascularization ▪ aortic aneurysm intervention ▪ peripheral vein disease 	<p>therapeutic amputation of a lower or upper extremity due to severe PAD</p> <p>surgical or endovascular revascularization of any artery except for the coronaries, carotids, intracerebral arteries or aorta</p> <p>resection and interposition of the thoracic or abdominal aorta</p> <p>deep vein thrombosis, pulmonary artery embolism</p>
diabetic end-organ damage/ complications	
<ul style="list-style-type: none"> ▪ diabetic microangiopathy ▪ diabetic foot syndrome ▪ hospitalization for hypo- or hyperglycemia 	<p>new diagnosis of diabetic retinopathy, neuropathy, or nephropathy</p> <p>due to diabetic neuropathy and/or PAD, with or without amputation</p> <p>with or without ketoacidosis or hyperosmolar coma</p>
renal	
<ul style="list-style-type: none"> ▪ major adverse kidney events (MAKE) ▪ acute kidney injury 	<p>end stage renal disease (transplantation or dialysis) or renal death</p> <p>stage AKIN I-III with or without acute dialysis</p>
death	
<ul style="list-style-type: none"> ▪ all-cause mortality ▪ death caused by infection 	<p>any vascular or non-vascular death or death by an unknown cause</p> <p>in immunocompromised vs. in non-immunocompromised patients</p>


<ul style="list-style-type: none"> ▪ death caused by terminal kidney disease ▪ death caused by cancer ▪ death caused by COVID-19 ▪ death caused by other reasons ▪ unknown cause of death 	<p>death directly attributable to kidney failure without sufficient renal replacement therapy</p> <p>death in the context of terminal cancer or cancer therapy complications</p> <p>any death that occurs during hospitalization for COVID-19 e.g., death by suicide, death following trauma</p> <p>this category can only be adjudicated in exceptional cases</p>
<p>other hospitalizations</p> <ul style="list-style-type: none"> ▪ hospitalization for or with neuro-psychiatric reasons ▪ hospitalization for epilepsy ▪ hospitalization for endocrinological/ metabolic reasons ▪ hospitalization or new diagnosis of cancer ▪ any other hospitalization 	<p>schizophrenia, depression, bipolar disorder, anxiety disorder, delirium, dementia</p> <p>first epileptic seizures, epilepsy, status epilepticus</p> <p>hypothyroidism, hyperthyroidism, hyponatremia, non-alcoholic fatty liver disease</p> <p>any kind of cancer</p> <p>any hospitalization that does not meet criteria of a more specific endpoint</p>
<p>COVID-19 related outcomes</p> <ul style="list-style-type: none"> ▪ in-hospital treatment for COVID-19 	<p>with or without ICU admission, with or without mechanical ventilation or ECMO</p>
<p>medical consequences of BeLOVE incidental findings</p>	<p>medical treatment related to urgent incidental findings from MRI, ECG, 24hr-ECG, 24hr blood pressure, echocardiography, optical fundus examination, blood samples</p>
<p>* secondary endpoints are defined and coded in much more detail in a comprehensive inventory</p>	
<p>Value-based outcomes (quality of life) §</p>	
<ul style="list-style-type: none"> ○ health related quality of life 	<p>PROMIS Profile®</p> <p>EQ5d5l</p> <p>SF 36 **</p>
<ul style="list-style-type: none"> ○ domain specific quality of life** 	<p>depression: PROMIS; PHQ-8</p> <p>anxiety, physical function, pain, fatigue, sleep, social roles: PROMIS</p>
<ul style="list-style-type: none"> ○ disease-specific quality of life 	<p>heart failure: KCCQ, MLHFQ</p> <p>angina: Seattle Angina Questionnaire</p> <p>diabetes: ADDQoL</p> <p>stroke: SSQoL</p>
<p>§ value-based outcomes are also measured during ~1hr basic deep phenotyping</p> <p>** these measures are not performed during telephone visits</p>	
<p><i>Abbreviations:</i> TAVI = transcatheter aortic valve implantation; STEMI= ST-segment elevation myocardial infarction; NSTEMI= non--segment elevation myocardial infarction; ECMO= extracorporeal membrane oxygenation; ICU = intensive care unit; PROMIS= patient reported outcome measure instrument system; EQ5d5l = five-level scale of the EuroQoL group; SF36= short form 36; PHQ 8= depression related part of the Patient Health Questionnaire sparing suicidality; KCCQ = Kansas City Cardiomyopathy questionnaire; MLHFQ= Minnesota Living with Heart Failure Questionnaire; ADDQoL= Audit of Diabetes Dependent Quality of Life; SSQoL= Stroke Specific Quality of Life Scale</p>	

Endpoint assessment and adjudication procedures

Assessment of relevant new clinical events during follow up

Assessment of new clinical events is performed repeatedly (after ~30, ~60 and ~90 days and biannually) in every participant by a specialized team of BTU staff. All available patients are interviewed (see clinical events interview table 3 in the main paper) for new clinical events (see sup. table 7) at deep phenotyping and all telephone visits. Self-reported patient information on clinical events by participants or proxies will only be considered as an endpoint if it can be validated by medical documents from hospitals or family doctors. Systematic research of the Charité hospital information system (HIS) is carried out irrespective of declarations made

during the participant interview every 6 months. For participants that are unavailable for questioning, the assessment is expanded by inquiries of citizen registration offices and family doctors. In case of death any available information concerning the cause of death including the latest medical reports, death certificates and information by family doctors and proxies are obtained (see suppl. figure 2 for an overview of the research methods). Further, repeated queries of diagnostic data from health insurance companies shall be implemented as soon as possible as an additional measure.



Supp. Figure 2: Endpoint assessment is performed at every upcoming deep phenotyping or telephone visit. The hospital information system (HIS) of the Charité is researched for any new treatments or events in any case. The use of all other research methods are depending on the availability of the participant. In unavailable participants the family doctor is contacted for additional information on any new clinical events (e.g., that were not treated within the Charité). Since registration of all citizens is mandatory in Germany the current address and information about the vital status, that is information about death and date of death can usually obtained by the citizen registration office databank. If a participant deceased in a hospital, all relevant last medical reports and if available, any autopsy report will be obtained. In cases of death outside of a hospital death certificates and any other available information by the family doctor, by proxies or autopsy reports will be obtained. All available participants will be interviewed concerning clinical events. Importantly, every self-reported event will be validated by documents from HIS, other hospitals or the family doctor and reported events that could not be validated will not be considered as endpoints. Finally, the whole process of endpoint research is documented in the study databank and all medical documents obtained are forwarded to the endpoint adjudication board. (*) means, that this source data is considered whenever it is available.

Endpoint adjudication procedures

Endpoint adjudication is primarily and constantly carried out by a group of physicians that is reviewing all medical information on clinical events retrieved during the follow up. All endpoints of interest are predefined and coded in an extensive inventory containing standardized definitions which is providing the tool for a standardized adjudication procedure (see supp. table 7 for an overview). Every medical document is reviewed for any of the endpoint-defining events as defined in the inventory, therefore multiple secondary endpoints may be extracted from a single document. Further, data on the patient history in every document is compared to already existing endpoint data in the study database. Additional medical source will be obtained for all potential endpoint data that is missing in our database.

For every potential MACE (see supp. figure 3) or in any case of death that cannot be determined with absolute certainty the final adjudication is carried out by a superior endpoint committee consisting of the clinical PIs of the study (see supp. figure 4). Only events that manifested clinically are considered as MACE while events that are evident by paraclinical exams only (e.g., signs of incidental stroke or myocardial infarction on neuroimaging) are not.

Potential MACE

Definition


- *all* deaths
- *any* in hospital treatment (or office-based treatment with sufficient source data) for
 - ACS, myocardial infarction, unstable angina, angina or
 - acute heart failure, acute worsening of chronic heart failure, acute dyspnea or
 - stroke, apoplexia, cerebral hemorrhage, transient ischemic attack

as the main diagnosis at admission *or* at discharge *or* when mentioned as a differential diagnosis *or* as an acute secondary diagnosis

Diagnostic certainty of the preliminary adjudication of potential MACE

- *certain*: the event is a certain MACE event *or* certainly no MACE *or* a certain type of non-vascular death as defined by the endpoint catalogue
- *in doubt*: the event is a MACE event *or* no MACE event *or* a specific type of non-vascular death by the preliminary opinion of the working group members but some uncertainty given the definitions exists
- *uncertain*: a MACE event cannot be ruled out but no clear judgement was possible (e.g. due to insufficient information with all available data sources exhausted)

Supp. figure 3 Definition of potential MACE events and categories to be used to rate the diagnostic certainty of preliminary adjudication by the endpoint working group. For all events categorized as in doubt or uncertain final adjudication is carried out by the internal endpoint committee.



Supp. figure 4 Endpoint adjudication is primarily carried out by the 1 endpoint working group of study physicians who examine every document obtained during endpoint research for contained endpoints. Endpoints are defined in a comprehensive catalogue defining multiple standardized endpoints categorized in 9 chapters (cardiovascular events, cerebrovascular events, peripheral vascular events, diabetes complications, renal events, other clinical events (including any kind of hospitalization not defined elsewhere, medical treatments as a consequence of BeLOVE findings management, COVID-19 associated events and events occurring during the acute phase of the index event). The definition* of potential MACE and the categories for rating the certainty of their adjudication are described in *supp. figure 4*.

Methods used to improve retention

Participants receive several calls and letters to remind them of their appointments. Different protocols with shorter vs. longer examination times are available for the on-site visits to accommodate both physically impaired participants and those who are physically more resilient and highly motivated (see figure 2). Communication of individual study results (which is embedded in incidental findings management, see below) is conducted in a highly standardized

process, that is transparently communicated to the participants during informed consent. Furthermore, participants are informed about the overall study progress by newsletters.

Data management, Quality assurance (QA) and Quality control (QC)

Data management is conducted by BeLOVE's own data management team in close cooperation with the clinical study center (CSC) of the Charité – Universitaetsmedizin Berlin. BeLOVE collects and manages study data using the secure, open-source web-based software platform REDCap hosted at Charité – Universitaetsmedizin Berlin [3, 4]. Manually captured data (e.g., self-administered questionnaires, interview results, and results of bedside examinations) are collected using a web-based central electronic case report forms (eCRF) on a tablet. Data from medical devices are captured automatically to the Health Data Platform (HDP) of the Charité, which includes an archive for raw data as well as a structured repository for metadata. Similarly, measurements performed on biosamples that are not stored in the biobank is processed using a central laboratory information management system (LabVantage). The repository for all laboratory data, including metadata, is centrally managed. This management includes central execution of data validation procedures as well as data query management. The independent third trust party of the Charité, which is separated from the main study database, is keeping a master participant index and is managing pseudonymization and a central electronic informed consent management.

Our QA and QC concept was developed and will constantly be updated, in close cooperation with the central structures for internal and external quality management at the Clinical Study Center (CSC) of the Charité – Universitaetsmedizin Berlin. Our concept is in line with principles and guidelines for Good Clinical Practice (ICH-GCP), Good Laboratory Practices (GLP) and Good Epidemiological Practice (GEP).[5] Standard operating procedures for all elements of data collection as well as a delegation log of responsibilities have been implemented to standardize our efforts. This includes also the periodic calibration of data capturing devices

to reduce measurement errors and batch effects. More importantly, the training and certification of all personnel involved in collection of data and biosamples, as well as the continuous testing of our data collection procedures will help to ensure high-quality data collection throughout the study period. This is supported by data monitoring in the responsibility of the CTO ensuring that rights and well-being of participants are protected, that the reported study data are accurate, complete, and verifiable, and that the conduct of the study complies with the currently approved protocol/amendment(s), with GCP, and with the applicable regulatory requirements.

Research questions (examples) addressed in BeLOVE

Supp. table 7: Examples for research questions/ hypotheses to be investigated by specific phenotyping methods

Research question/Hypotheses	Method	main outcomes
Myocardial structure as determined by cardiac MRI predicts major adverse cardiovascular events	cardiac MRT	MACE
Stroke induced functional and structural alterations in the central autonomic network predict long-term cardiac alterations	cerebral MRI, cardiac MRI, Echocardiography, clinical parameters	myocardial morphology and cardiac function, Diagnosis of Heart Failure
Alterations in myocardial morphology and cardiac function predict cognitive decline and cerebrovascular events	cerebral MRI, cardiac MRI, Echocardiography, clinical parameters	Cognitive decline, cerebrovascular events
Cognitive decline after ischemic stroke is determined by multiple factors such as genetic, inflammatory, metabolic, structural, psychosocial, and lifestyle predispositions.	cerebral MRI, EEG, Cognitive measures (MOCA; CANTAB), bio sampling, PROMs	Cognitive decline, cerebrovascular induced brain lesions
Fasting, feeding, resting, and physical activity induce different dynamics of metabolic biomarker profiles predicts future cardiovascular events	Nutritional and physical (spiroergometry) challenge, bio sampling,	MACE, secondary cardiovascular events
Glucose variation as measured by continuous glucose monitoring improves prediction of recurrent cardiovascular events and health outcome	Continuous glucose monitoring, bio sampling	MACE, secondary cardiovascular events
Patterns of physical activity, sedentary behavior, diet, and psychosocial stress predict cardiovascular outcomes	Physical Activity, Food diaries, Eating questionnaires, PROMs, metabolomics	MACE, secondary cardiovascular events
Advanced assessment of diabetic microvascular complications is able to identify biomarkers for adverse macrovascular outcomes	Somatosensory phenotyping, Ophthalmologic phenotyping, bio sampling	Diabetic neuropathic and retinopathic patterns, MACE
Genetic and epigenetic variability are associated risk factors for cardiovascular events	Genomics	MACE
Alterations of microbiome-driven immunological and metabolic homeostasis predict cardiovascular risk	Stool sampling, bio sampling, immunophenotyping	MACE, secondary cardiovascular events

Addressing potential Sources of bias

There are methodological challenges in BeLOVE as in any other clinical observation cohorts. Patients consenting to participate in the study represents a selection of patients who would be recruitable. To estimate this selection bias, we compare patient characteristics of participants to aggregated data (sex, age, comorbidity) of all other patients treated at Charité and main hospital diagnosis of CVD. In addition, the number of patients who are able to participate in face-to-face visits may decrease over time due to worsened disease status or other issues. We will address this potential attrition bias with a comprehensive concept of active and passive patient follow-up, such as telephone interviews and the use of hospital registry data. Additionally, reasons for drop out will be documented if participants are contacted and withdraw from the study. Other types of bias such as collider stratification bias or reverse causation need to be considered in analyses of the BeLOVE study. Thus, conditioning on disease groups may open up a backdoor path, and thus violate the conditional exchangeability assumption. Such backdoor paths can be identified using Directed Acyclic Graphs (DAGs). In BeLOVE, we will therefore ensure that specific research questions will be put into the framework of sound DAG theory. Therefore, data collection regarding pre-existing risk factors is just as important as the data collection on current potential risk factors.

Reverse causation is another concern for potential bias when studying patients with pre-existing diseases. This type of potential bias does not uniformly apply to the study design per se but is dependent on the underlying research questions. In recent years, situations have been identified in which reverse causation has been an issue, and several approaches have been suggested to identify reverse causation bias, such as serial tracking of data, stratified analysis, and instrumental variable analysis.[6] Because of the intensive monitoring of the patients in the BeLOVE cohort and the close integration with the Charité electronic health record system, serial tracking will be an efficient way to be included into the analysis. In addition, given the deep phenotyping in BeLOVE and the assessment of many potential risk factors we will be able to conduct pre-specified stratified analyses (e.g., by age or follow-up time) to assess the possibility of reverse causation.

Sample size justification and detailed power statement

While many different types of analyses and models will be applied in BeLOVE, time-to-event analyses will be a major focus. The Cox proportional hazards regression model is the basic approach for modeling time to event data. Other models for recurrent or competing events that will also be applied are all extensions of this well-known Cox-model. Therefore, we based our power considerations on the Cox model approach.


The sample size calculation of a Cox model is influenced by several factors, for which we have made the following assumptions:

- The anticipated power value (set as 80%).
- The number or percentage of observed events at the investigated follow-up time point. For BeLOVE, it is assumed that within the 1-year follow-up 8-12% of the patients experience a new cardiovascular event of any type.^[7-9] For the individual disease entities, the event rates might differ. Note that the BeLOVE study is planned with total follow-up time of 10 years. With an increasing follow-up period, the number of expected events will increase and as a consequence, the power will increase as well. Therefore, the considerations made in here for the one-year follow-up define a conservative scenario and even better power values can be expected for longer follow-up times.
- The type, the distribution and the number of independent variables included in the model. For the sake of simplicity, we assumed two types: continuous and binary. For continuous we have modelled the exposure per standard deviation increase (standardized effect) and for binary variables we assumed equal group sizes (50% prevalence of the exposure of interest).
- The anticipated effect of the risk factor, expressed for the Cox model as the hazard ratio (HR) or the logarithm of the HR (i.e., beta-coefficient).


- The anticipated degree of correlation among risk factors of interest and all other independent variables in the model, which is given as pseudo- R^2 , which lays within $[0;1]$. Values close to 0 indicate that the risk factor of interest is independent of all other covariates. As there are always multiple factors associated with the final outcome, a correlation among independent variables of 0.3 seems often more reasonable.

Based on these parameters and assumptions, we constructed two figures that provide an overview of the precision and minimally detectable effects for continuous exposures modeled per standard deviation increase (suppl. figure 5) and binary exposures (suppl. figure 6), respectively that can be expected. Specifically, the figures investigate a range of sample sizes from 1200 to 7800. The graphs were obtained by the “power” package from STATA 14.0 with the following details:

1. `power cox, sd(1.0) n(600 1200:8000) r2(0 0.3) failprob(0.08 .12) effect(hratio) power(0.8) direction(upper)`
2. `power cox, sd(0.5) n(600 1200:8000) r2(0 0.3) failprob(0.08 .12) effect(hratio) power(0.8) direction(upper)`



Supp. figure 5: BeLOVE Power Scenarios: minimally detectable effect after one year of follow-up: **continuous exposure**, per SD




Supp. figure 6: BeLOVE Power Scenarios: minimally detectable effect after one year of follow-up: **binary exposure** (50%)

As an exemplary interpretation, for a two-sided significance level of 5%, a power of 80%, and no correlation between the predictors and an annual event proportion of 8%, the minimal detectable effect in 7000 participants is HR 1.13 (black line), which is lowered to HR 1.10 when a 12% annual incidence of outcome is assumed (green line). This shows that with all patients in a combined analysis, BeLOVE has sufficient statistical power to pick up small effect sizes. Our calculations also include more conservative scenarios, e.g. if the study population at 1 year is reduced due to loss-to-follow-up, or in case of subgroup analyses in patients with one specific disease. Moreover, there will be the need to adjust for other covariates as for the predictor of interest and these set of predictors will usually be correlated. The figure shows these different scenarios, by varying the sample size as well as plotting separate lines for a single independent variable ($R^2=0$) as well as for several correlated independent variables, for example, adjusted for age, sex, and other traditional cardiovascular risk factors ($R^2 = 0.3$). It can be seen that if the risk factor of interest is correlated to other independent variables (blue and yellow lines), the required sample sizes are larger than for uncorrelated independent variables (black and green

lines). The flattening of the lines with increasing sample sizes indicate that the added precision obtained from increasing sample size reduces with sample sizes above N=2000.

A similar picture, but with higher minimally detectable hazard ratios, is obtained when looking at the minimally detectable differences for binary exposures with a prevalence of 50%.

Recruitment, acute and 1st deep phenotyping visits performed during first study phase (implementation)



Supp. Figure 7: Patients recruited during first study phase between July 18, 2017 and December 31, 2020. Originally, 2248 participants were recruited and signed the informed consent. Of those, 343 were excluded for screening failure or dropped out of the study (by withdrawal, death etc.) before any baseline data could be obtained. Therefore 1905 participants were available for phenotyping and follow up. Acute phenotyping was performed at max. 7 days after the acute event or study inclusion in the diabetes arm. Deep phenotyping was performed after ~90 days, 2 years and 4 years. Please note, that in the initial study phase deep phenotyping was offered every second year. Only participants that joined the 1st deep phenotyping could participate in the later deep phenotyping visits. Follow up by telephone is continued for all participants that did not end study participation. * 848 (96.6%) participants of the 1st deep phenotyping also joined acute phenotyping before; figure is based on data export from 15 May 2023

Baseline characteristics of patients recruited in the first study phase (implementation)


Supp. table8: Baseline characteristics at enrollment of patients recruited during the first study phase. Data is based on self-reported history which was largely validated by reviewing medical records. Data is related to the time before event or recruitment in the diabetes group. Except for ischemic stroke/TIA, myocardial infarction, acute heart failure and peripheral artery disease primary diagnosis of the condition during the treatment of the index event was also considered. Available number of data for every parameter are presented in []. Table is based on data export from 15 May 2023.

	total cohort	subcohorts				
		ACS	AHF	Stroke	AKI	Diabetes
total participants n	1905	432	182	758	242	291
age, mean (SD) [n total]	66.0 (13.0)[1905]	65.0 (12.0) [432]	71.0 (10.9)[181]	67.5 (12.7)[768]	63.0 (15.9)[242]	63.1 (12.0)[291]
sex, female, n (%) [n total]	680 (35.7) [1905]	121 (28.0) [432]	61 (33.5) [181]	282 (37.2) [768]	103 (42.6) [242]	113 (38.8) [291]
hypercholesterolemia, n (%) [n total]	1646 (91.5) [1799]	418 (98.4) [425]	143 (83.1) [172]	694 (93.7) [741]	136 (70.5) [193]	255 (95.1) [255]
arterial hypertension, n (%) [n total]	1627 (88.2) [1845]	425 (98.4) [432]	169 (93.4) [181]	625 (85.0) [735]	157 (71.0) [221]	251 (90.9) [276]
diabetes mellitus, n (%) [n total]	801 (42.7) [1892]	148 (34.3) [431]	98 (54.1) [181]	171 (22.6) [757]	93 (40.1) [232]	291 (100) [291]
coronary artery disease, n (%) [n total]	749 (40.3) [1859]	398 (93.4) [426]	107 (59.1) [181]	107 (14.2) [752]	58 (26.1) [222]	79 (28.4) [278]
atrial fibrillation, n (%) [n total]	467 (25.1) [1857]	74 (17.4) [426]	122 (67.4) [181]	164 (21.8) [752]	59 (26.5) [223]	48 (17.5) [275]
current smoking, n (%) [n total]	410 (22.9) [1792]	132 (32.2) [410]	26 (15.7) [166]	155 (21.6) [717]	49 (22.3) [220]	48 (17.2) [279]
former smoking n (%)	532 (29.6)	111 (27.1)	62 (37.3)	208 (29.0)	76 (34.5)	75 (26.8)
Hx of chronic heart failure, n (%) [n total]	345 (19.5) [1770]	72 (17.8) [404]	155 (88.1) [176]	46 (6.7) [691]	37 (16.8) [220]	35 (12.5) [279]
Hx of ischemic stroke or TIA, n (%) [n total]	271 (14.1) [1866]	30 (7.0) [426]	26 (14.4) [181]	187 (24.9) [752]	14 (6.3) [223]	14 (5.0) [279]
Hx of myocardial infarction, n (%) [n total]	241 (13.0) [1860]	86 (20.2) [426]	44 (24.3) [181]	63 (8.4) [752]	24 (10.8) [222]	24 (8.6) [279]
Hx of carotid artery stenosis, n (%) [n total]	133 (7.4) [1793]	18 (4.4) [407]	1 (0.6) [162]	89 (12.3) [725]	7 (3.2) [221]	18 (6.5) [278]
Hx of peripheral artery disease, n (%) [n total]	129 (6.9) [1858]	29 (6.8) [426]	23 (12.7) [181]	42 (5.6) [752]	19 (8.6) [221]	16 (5.8) [278]
Hx of acute heart failure, n (%) [n total]	113 (6.1) [1854]	7 (1.6) [426]	83 (45.9) [181]	11 (1.5) [752]	7 (3.2) [218]	5 (1.8) [277]

Study design adjustments


Several adjustments of the study design were necessary. First, while we intended to include high-risk patients in our study, we observed a misbalance among study arms in a way that in some arms patients were too sick to attend study visits. Therefore, we adapted the inclusion and exclusion criteria particularly of the AHF-arm to facilitate participation of less severely affected patients and in the chronic high risk-arm to achieve a more balanced design. Further, the original design of BeLOVE included an additional fifth arm of patients with recent acute kidney injury (AKI); however, this arm was terminated because health-impairment in this population was too severe to participate in the study, and no option for adaption of the inclusion or exclusion criteria was deemed feasible. In consequence, the total sample size aimed for was reduced from 10,000 to 8,000 patients. Second, it was originally planned to have deep-phenotyping visits every two years for each patient in addition to the 90-day visit. Because of budget restrictions these visits have been dropped from the main protocol. Third, the study program was tightened to reduce the burden of clinical examinations for the participants and to optimize adherence rates. A detailed timeline and description of all relevant modifications can be found in supp. figures 8 and 9 and supp. table 9.

Timeline of study design adjustments – part 1



Supp. figure 8: Timeline of study design adjustments between July 18 2017 and December 31st, 2021. Timeline is continued in supp. figure 10. Please see supp. Table 10 for more details on the adjustments. AHF, acute heart failure NYHA \geq IIIb; ACS, acute coronary syndrome; Stroke, ischemic stroke, TIA, non-traumatic intracerebral hemorrhage and cerebral vein thrombosis; AKI, acute kidney injury \geq AKIN II; p.e., post event date; p.i., post inclusion date; TOD; target organ damage

Timeline of study design adjustments – part 2



Supp. figure 9: Timeline of study design adjustments between Jan 1 2021 and March 1st 2023. Please see supp. Table 10 for more details on the background and implications of the major adjustments. AHF, acute heart failure NYHA \geq II; ACS, acute coronary syndrome; Stroke included ischemic stroke, TIA, and non-traumatic intracerebral hemorrhage; AKI, acute kidney injury \geq AKIN II; p.e., post event date; p.i., post inclusion date; CANTAB, Cambridge Neuropsychological Test Automated Battery; * phenotyping in 2 year intervals may be continued for pat. subsets if additional funding is available

Major adjustments of the study design during study implementation

Supp. table 9: Major adjustments of the study protocol during the initial implementation and current second phase of the study

Topic/ Study procedure	Previous status	Experience	Major adjustment
inclusion criteria acute kidney injury (AKI)	a subcohort of patients with AKI KDIGO stage AKIN \geq 2 as an additional CV high risk population was recruited since January 2018	recruitment and retention of this subcohort was critical due to severe overall health impairment which was also expressed by a high mortality- (~25%) and withdrawal (~17%) rate	<ul style="list-style-type: none"> recruitment was terminated in November 2021 a total 252 patients were recruited from January 2018 until November 2021 currently 140 participants remain in the study for whom a telephone follow up is continued the subcohort will be described in more detail in forthcoming publications
inclusion criteria, chronic CV risk arm	initial definition was pts. with diabetes mellitus type 2 or prediabetes with target organ damage	<ul style="list-style-type: none"> Recruitment: diabetes: n= 219; prediabetes n=2 1st redefinition June 18, 2019: recruitment of prediabetes was terminated; diabetes typ2 (T2DM) + microangiopathy (nephropathy, retinopathy, or neuropathy) or + macroangiopathy (cerebrovascular disease, CAD, or PAD) was defined as eligible; n=90 pts were recruited until Aug 17, 2020 there were concomitant concerns about the limitation of the chronic risk group to diabetics only 2nd redefinition Aug 17, 2020: due to concomitant concerns about the limitation of the chronic risk group to diabetes only; patients with at least to major risk factors (T2DM, arterial hypertension, or hypercholesterolemia) and target organ damage (atherosclerosis, chronic kidney injury, hypertensive heart disease, diabetic or hypertensive retinopathy, diabetic nephropathy, or diabetic neuropathy); pts. with any history of acute stroke, TIA, AHF, ACS or AKI were excluded from recruitment n= 99 patients recruited under this definition; > 70% were diabetics and recruitment of all candidates was heavily impeded by the exclusion of previous acute events 	<ul style="list-style-type: none"> 3rd redefinition February 2023: according to the CV very high risk definitions proposed by the ESC (2029, 2021) which includes patients with previous acute CV events, patients with severe chronic kidney injury, atherosclerosis, T2DM+ arterial hypertension+ hypercholesterolemia, diabetic microangiopathy or very high risk SCORE2/SCORE2-OD patients with previous CV events or AHF are only excluded if such events occurred within the last 12 months the adjustment does not affect the majority of participants who have been recruited previously, as they will remain eligible under the new criteria
inclusion criteria, stroke arm	cerebral venous thrombosis (CVT) was defined as a possible inclusion criterion	no patients with CVT could be recruited during the first study phase	<ul style="list-style-type: none"> CVT was discarded as an inclusion criterion central retinal artery occlusion was defined as a ischemic stroke equivalent

Topic/ Study procedure	Previous status	Experience	Major adjustment
			<ul style="list-style-type: none"> the adjustment does not affect participants who have been recruited previously, as they will remain eligible under the new criteria
inclusion criteria, acute heart failure arm	AHF was defined as dyspnea \geq NYHA IIIb and NTproBNP \geq 300 pg/nl or MRproANP \geq 120 pmol/l	recruitment and retention were found to be compromised by the severity of the overall health impairment of these patients	<ul style="list-style-type: none"> AHF \geq NYHA II was defined to be sufficient for study inclusion specific cut of values for biomarkers were no longer mandatory the adjustment does not affect participants who have been recruited previously, as they will remain eligible under the new criteria
exclusion criteria general	patients with an acute event, that did already experience a previous event within the last 3 months were excluded from the study	this practice did significantly limit the number of eligible patients, in particular in the AHF arm	<ul style="list-style-type: none"> criterion was discarded since Jan 1st, 2021 change does not affect participants who have been recruited previously, as they will remain eligible under the new criteria. the adjustment does not affect participants who have been recruited previously, as they will remain eligible under the new criteria
follow up phenotyping schedule	additional and repeated deep phenotyping visits with a program equivalent to the ~day 90 visit u to every 2 years was offered to the first ~3000 participants	current funding does not allow to continue additional deep phenotyping beyond day 90	<ul style="list-style-type: none"> deep phenotyping visits beyond day 90 have not been performed since January 1st, 2023 number and rates of pts. that up till then participated in deep phenotyping after 2,4 and 6 years are shown in supp. figure 8 results of the phenotyping performed will be analyzed for publication additional phenotyping may be continued for patient subsets currently recruited if additional funding is available in the future
follow up phenotyping schedule	deep phenotyping was an 8hr program splitted between two days without other options	8hr phenotyping was not feasible for many old and/or very ill participants and the lack of other options impaired recruitment and retention	<ul style="list-style-type: none"> participants can chose between an 4hr standard program or 4hr standard + 4 hr module program a ~1hr basic program is available for participants that would otherwise not participate in deep phenotyping at all for health-related and other reasons
follow up discaredd methods	<ul style="list-style-type: none"> blood samples obtained during acute and deep phenotyping were used for immunophenotyping 	<ul style="list-style-type: none"> immunophenotyping and hair sample analysis cannot be continued due to funding restrictions COVID-19-related measures were stopped due to the declining incidences and increasing reates of seroconversion 	<ul style="list-style-type: none"> Methods and associated research questions will be described in detail in forthcoming publications. Available sample sizes are: Immunophenotyping was performed from blood samples of ~1000 participants

Topic/ Study procedure	Previous status	Experience	Major adjustment
	<ul style="list-style-type: none"> besides saliva, hair samples were obtained during day ~90 deep phenotyping to investigate the impact of the pandemic on the CV high-risk cohort, additional phenotyping (3 months post infection) and measurement of SARS-CoV2-antibodies was offered to the participants 		<p>during acute and of ~750 participants of ~day 90 deep phenotyping</p> <ul style="list-style-type: none"> hair samples were obtained from 339 participants additional phenotyping after COVID-19-infection was performed in 34 participants; data will be shared with the German National Pandemic Cohort Network (NAPKON) between August 2020 and March 2022 <p>SARS-CoV-2 antibodies were obtained at least once 1362 participants in</p>
follow up new methods	several measures of deep phenotyping were not yet available by the start of the first study phase	the following method were implemented during the course of the study (see timeline supp. figure 9) : standard deep phenotyping: optical funduscopy, optical coherence tomography (OCT), bodyplethysmography, Montreal Cognitive Assessment (MoCA); module program: 24hr - ECG	all methodes are well established and measures are continued during phneotyping

Supplemental References

1. Mach, F., et al., *2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk*. Eur Heart J, 2020. **41**(1): p. 111-188.
2. Visseren, F.L.J., et al., *2021 ESC Guidelines on cardiovascular disease prevention in clinical practice*. Eur J Prev Cardiol, 2022. **29**(1): p. 5-115.
3. Harris PA, et al. *Research electronic data capture (REDCap) – A metadata-driven methodology and workflow process for providing translational research informatics support*, J Biomed Inform. 2009. **42**(2):377-81
4. Harris PA, et al. *The REDCap consortium: Building an international community of software partners*, J Biomed Inform. 2019 [doi: 10.1016/j.jbi.2019.103208]
5. Hoffmann, W., et al., *Guidelines and recommendations for ensuring Good Epidemiological Practice (GEP): a guideline developed by the German Society for Epidemiology*. Eur J Epidemiol, 2019. **34**(3): p. 301-317.
6. Sattar, N. and D. Preiss, *Reverse Causality in Cardiovascular Epidemiological Research: More Common Than Imagined?* Circulation, 2017. **135**(24): p. 2369-2372.
7. Amarenco, P. and T.o. Steering Committee Investigators of the, *Risk of Stroke after Transient Ischemic Attack or Minor Stroke*. N Engl J Med, 2016. **375**(4): p. 387.
8. Jernberg, T., et al., *Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective*. Eur Heart J, 2015. **36**(19): p. 1163-70.
9. Maggioni, A.P., *Epidemiology of Heart Failure in Europe*. Heart Fail Clin, 2015. **11**(4): p. 625-35.